<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease - Fraser, A - 2022 | Cochrane Library</title> <meta content="Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease - Fraser, A - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013343.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease - Fraser, A - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013343.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013343.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Ashley Fraser" name="citation_author"/> <meta content="Auckland DHB" name="citation_author_institution"/> <meta content="a_fraser1@hotmail.com" name="citation_author_email"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013343.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013343.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013343.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013343.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adjuvants, Immunologic [therapeutic use]; Anti-Bacterial Agents [therapeutic use]; *Bronchitis, Chronic [drug therapy]; Disease Progression; *Pulmonary Disease, Chronic Obstructive [drug therapy]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013343.pub2&amp;doi=10.1002/14651858.CD013343.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013343\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013343\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013343.pub2",title:"Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease",firstPublishedDate:"Nov 14, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013343.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013343.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013343.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013343.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013343.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013343.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013343.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013343.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013343.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013343.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2787 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013343.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0080"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-sec-0072"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/appendices#CD013343-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/supinfo/CD013343StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/supinfo/CD013343StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information#CD013343-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ashley Fraser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information#CD013343-cr-0005">Phillippa Poole</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information/en#CD013343-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013343.pub2">https://doi.org/10.1002/14651858.CD013343.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013343-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013343-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013343-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013343-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013343-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013343-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013343-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013343-abs-0001" lang="en"> <section id="CD013343-sec-0001"> <h3 class="title" id="CD013343-sec-0001">Background</h3> <p>Individuals with chronic obstructive pulmonary disease (COPD) or chronic bronchitis may experience recurrent exacerbations, which negatively impact prognosis and quality of life, and can impose a significant socioeconomic burden on the individual and wider society. Immunostimulants are a broad category of therapies that may theoretically enhance non‐specific immunity against several respiratory insults, thereby reducing exacerbation risk and severity. However, evidence to date for their use in this population is limited. </p> </section> <section id="CD013343-sec-0002"> <h3 class="title" id="CD013343-sec-0002">Objectives</h3> <p>To determine the efficacy of immunostimulants in preventing respiratory exacerbations in adults with chronic obstructive pulmonary disease, chronic bronchitis, or both. </p> </section> <section id="CD013343-sec-0003"> <h3 class="title" id="CD013343-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest literature search was conducted on 25 January 2022.  </p> </section> <section id="CD013343-sec-0004"> <h3 class="title" id="CD013343-sec-0004">Selection criteria</h3> <p>We included parallel randomised controlled trials (RCTs) that compared immunostimulant therapy, administered by any method and with the intention of preventing (rather than treating) exacerbations, with placebo for a minimum treatment duration of one month in adults with chronic bronchitis or COPD, or both. We excluded participants with other respiratory conditions.  </p> </section> <section id="CD013343-sec-0005"> <h3 class="title" id="CD013343-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were number of participants with no exacerbations during the study period and all‐cause mortality, secondary outcomes were respiratory‐related mortality, quality of life, number of participants requiring antibiotics, exacerbation duration, respiratory‐related hospitalisation duration and adverse events/side effects. We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD013343-sec-0006"> <h3 class="title" id="CD013343-sec-0006">Main results</h3> <p>This review included 36 studies involving 6192 participants. Studies were published between 1981 and 2015. Duration ranged from three to 14 months. The mean age of study participants varied between 35.2 and 82 years. Twelve studies examined participants with COPD only. Seventeen studies reported baseline lung function values; most indicated a moderate‐to‐severe degree of airflow limitation. Nineteen studies indicated inclusion of participants with a mean baseline exacerbation frequency of two or more in the preceding year. Immunostimulants investigated were OM‐85, AM3,<i> </i>RU41740 (Biostim), Ismigen, Diribiotine CK, thymomodulin, pidotimod, D53 (Ribomunyl), Lantigen B, Symbioflor, and hyaluronan; routes of administration were oral, sublingual, and subcutaneous. The risk of bias of the included studies was mostly low or unclear. </p> <p>Participants receiving immunostimulants for a mean duration of six months were slightly more likely to be free of exacerbations during that time (odds ratio (OR) 1.48, 95% confidence interval (CI) 1.15 to 1.90; 15 RCTs, 2961 participants; moderate‐certainty evidence). The overall number needed to treat with immunostimulants for a mean of six months, to prevent one participant from experiencing an exacerbation, was 11 (95% CI 7 to 29). This outcome was associated with a moderate degree of unexplained heterogeneity (I<sup>2</sup> = 53%). Type of immunostimulant, baseline lung function, baseline exacerbation frequency, treatment duration, and follow‐up duration did not modify the effect size, although due to heterogeneity and limited study and participant numbers within some subgroups, the validity of the subgroup treatment effect estimates were uncertain. </p> <p>Immunostimulants probably result in little to no difference in all‐cause mortality (OR 0.64, 95% CI 0.37 to 1.10; 5 RCTs, 1558 participants; moderate‐certainty evidence) and respiratory‐related mortality (OR 0.40, 95% CI 0.15 to 1.07; 2 RCTs, 735 participants; low‐certainty evidence) compared to placebo; however, the effects were imprecise and data quality limited the certainty of these results.  </p> <p>There was a small improvement in health‐related quality of life, as measured by the St George's Respiratory Questionnaire (SGRQ), with immunostimulant compared to placebo (mean difference −4.59, 95% CI −7.59 to −1.59; 2 RCTs, 617 participants; very‐low certainty evidence). The effect estimate just met the minimum clinically important difference (MCID) score of 4 units; however, the CI width means the possibility of a non‐meaningful difference cannot be excluded. </p> <p>The pooled result from five studies indicated that immunostimulants likely reduce the number of participants requiring antibiotics over a mean duration of six months (OR 0.34, 95% CI 0.18 to 0.63; 542 participants; moderate‐certainty evidence). This outcome had a low‐to‐moderate degree of heterogeneity (I<sup>2</sup> = 38%), but the direction of effect was consistent across all studies. </p> <p>There was no evidence of a difference in the odds of experiencing an adverse event with immunostimulant compared to placebo, over a mean duration of six months (OR 1.01, 95% CI 0.84 to 1.21; 20 RCTs, 3780 participants; high‐certainty evidence). The CI limits for the associated risk ratio (RR) did not cross thresholds for appreciable harm or benefit (RR 1.02, 95% CI 0.92 to 1.13). An additional seven studies reported no events rates in either study arm. </p> <p>Meta‐analyses were not performed for the outcomes of exacerbation duration and respiratory‐related hospitalisation duration, due to high levels of heterogeneity across the included studies (exacerbation duration: I<sup>2</sup> = 92%; respiratory‐related hospitalisation duration: I<sup>2</sup> = 83%). Results from an effect direction plot and binomial probability test for exacerbation duration indicated that a significant proportion of studies (94% (95% CI 73% to 99%); P = 0.0002) favoured intervention, possibly indicating that immunostimulants are efficacious in reducing the mean exacerbation duration compared to placebo. However, the degree of uncertainty associated with this estimate remained high due to data quality and heterogeneity. Three studies reported mean duration of respiratory‐related hospitalisation, two of which demonstrated a direction of effect that favoured immunostimulant over placebo. </p> </section> <section id="CD013343-sec-0007"> <h3 class="title" id="CD013343-sec-0007">Authors' conclusions</h3> <p>In participants with chronic bronchitis or COPD, we are moderately confident that treatment with immunostimulants is associated with a small reduction in the likelihood of having an exacerbation and a moderate reduction in the requirement for antibiotics. Low numbers of events limit interpretation of the effect of immunostimulants on all‐cause and respiratory‐related mortality. We are uncertain whether immunostimulants improve quality of life, and whether they are associated with a reduction in exacerbation and respiratory‐related hospitalisation durations, although immunostimulants were generally associated with a positive effect direction in the studies that examined these outcomes. Immunostimulants appear to be safe and well‐tolerated, and are not associated with an increased risk of adverse events.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013343-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013343-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013343-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013343-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013343-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013343-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013343-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013343-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013343-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013343-abs-0002" lang="en"> <h3>Is taking an immunostimulant on top of standard medications beneficial for people with chronic obstructive pulmonary disease, chronic bronchitis, or both? </h3> <p><b>Key messages</b> </p> <p>1. In people with chronic bronchitis or COPD, immunostimulants probably reduce the likelihood of a person having an exacerbation and of requiring antibiotics for an exacerbation. </p> <p>2. We are uncertain about the effect of immunostimulants on reducing the risk of death, improving quality of life, or on reducing the duration of flare‐ups or hospital stays. </p> <p>3. Immunostimulants are not associated with an increased risk of side effects.</p> <p><b>What are chronic obstructive pulmonary disease and chronic bronchitis?</b> </p> <p>Chronic obstructive pulmonary disease (COPD) and chronic bronchitis are common conditions that permanently affect the airways of the lungs. They are mainly caused by exposure to cigarette smoke or other air pollutants. People with COPD or chronic bronchitis may develop persistent symptoms of breathlessness, cough, and phlegm production, and are prone to flare‐ups (exacerbations) of these symptoms. Flare‐ups can be debilitating, worsen lung function over time, and cause further exacerbations. Several standard treatments exist to help prevent flare‐ups, which are recommended in almost all people who have a diagnosis of COPD. These mainly include quitting smoking, participating in exercise programmes, obtaining vaccinations to prevent infection, and using specific medications through an inhaler device.  </p> <p><b>What are immunostimulants?</b> </p> <p>Immunostimulants are a type of medication that are not widely used for the long‐term management of COPD or chronic bronchitis. Some scientists and doctors have suggested that immunostimulants, added to standard treatment, may help reduce the frequency and severity of flare‐ups in this patient group, by boosting the immune system response to triggers for exacerbations (such as infection with viruses or bacteria). </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out whether giving an immunostimulant medication, on top of standard treatment, reduced the frequency of flare‐ups in adults with COPD or chronic bronchitis. We also wanted to know whether immunostimulants reduced the risk of death, improved quality of life, and reduced the duration and severity of flare‐ups.  </p> <p><b>What did we do?</b> </p> <p>We searched for studies involving adults with COPD or chronic bronchitis or both, that took place over at least 12 weeks. Studies must have randomly divided participants into receiving either an immunostimulant or placebo (inactive replacement for a medicine), and directly compared the two groups. We included immunostimulants of any type and route of administration, although we did have prespecified criteria as to what constituted an 'immunostimulant' due to this term being relatively broad. </p> <p><b>What did we find?</b> </p> <p>We found 36 studies involving 6192 participants. These looked at a variety of immunostimulants over durations that ranged from three to 14 months. </p> <p>Results showed that participants receiving immunostimulants were slightly more likely to be free of exacerbations over an average duration of six months, compared to those who had received placebo. Treating 11 people with immunostimulants for six months would prevent one person from experiencing a flare‐up. We also found that immunostimulants likely reduced the number of participants requiring antibiotics for a flare‐up. Immunostimulants appeared to be safe, well‐tolerated, and not associated with an increased risk of side effects.  </p> <p>The impact of immunostimulants on death, quality of life, duration of flare‐ups, and the duration of hospital stays due to a flare‐up was unclear. Immunostimulants were generally favoured over placebo in most studies that looked at these outcomes.  </p> <p><b>What were the limitations of the evidence?</b> </p> <p>Overall, we are moderately confident in these results. Our confidence was reduced by how different some results looked between studies, the small number of studies included in some analyses, and in some instances by not having enough data or participant numbers to determine whether immunostimulants were truly better or the same as placebo. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date to January 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013343-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013343-sec-0080"></div> <h3 class="title" id="CD013343-sec-0081">Implications for practice</h3> <section id="CD013343-sec-0081"> <p>We graded the certainty of the evidence in this review to be moderate, meaning that the true effect is probably close to the estimate of the effect, but that further research is likely to have an important impact on our confidence in the estimate and may change the estimate. Our certainty in the pooled estimates was affected by several considerations, which led to downgrades in the associated level of certainty for most main outcomes.  </p> <p>Immunostimulants may slightly reduce the odds of an exacerbation in adults with chronic obstructive pulmonary disease (COPD) or chronic bronchitis (or both). Approximately 1 in 11 people may avoid experiencing an exacerbation, if all were to take treatment for a mean of six months. It is likely that immunostimulants are associated with a reduction in the requirement for antibiotics, which may suggest a reduction in the severity of exacerbations, although this relationship is only assumed. Immunostimulants probably result in little to no reduction in all‐cause and respiratory‐related mortality, but estimates are imprecise and data quality is limited. It is uncertain whether immunostimulants improve quality of life, and whether they reduce exacerbation duration or respiratory‐related hospitalisation duration (or both), although immunostimulants were generally associated with a positive effect direction in the studies that examined these outcomes. Immunostimulants appear to be safe and well‐tolerated and are not associated with an increased risk of adverse events.  </p> <p>Immunostimulants may be able to be considered as add‐on therapy to other gold‐standard, guideline‐based COPD therapies in those who continue to experience frequent exacerbations or who are requiring frequent courses of antibiotics for exacerbations, or both. They could be considered as an alternative option to any standard, usual‐care COPD therapy if this is not tolerated or cannot be used for any reason.  </p> </section> <h3 class="title" id="CD013343-sec-0082">Implications for research</h3> <section id="CD013343-sec-0082"> <p>Future studies may consider addressing the value of immunostimulants in populations with COPD or chronic bronchitis (or both) in study populations that are more well‐characterised, so that the subsets of patients who might benefit the most (or the least) from these therapies can be better identified. There should be a focus on people who have frequent or severe respiratory exacerbations and who are currently receiving maximal guideline‐based therapy. Populations should be stratified by the severity of their COPD (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>) – incorporating lung function and symptoms and exacerbation history – and use of concomitant medications. Study outcomes should include exacerbations, hospitalisations (COPD and all‐cause), mortality (COPD and all‐cause), health‐related quality of life scores measured using a validated tool, and adverse events. It may be useful to differentiate the baseline and post‐treatment severity of the exacerbations experienced into mild, moderate, or severe (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Follow‐up duration should be of sufficient length to allow for better representation of true exacerbation and mortality incidence, and the timing of the study should be considered (i.e. whether the study spans periods of the year when exacerbations are more likely).  </p> <p>Based on the challenges encountered in meta‐analysing and qualitatively interpreting the continuous outcome variables presented across the studies included in this review, we would advocate for the selection of robust, dichotomous treatment effect measures where possible; for example, by measuring the number of participants with/without an exacerbation, requiring antibiotics, or requiring hospitalisation, as opposed to event rate or mean number of events per participant. If event duration is to be measured, it should be specified whether the reported unit of time is per event or added cumulatively over the total study period. Time‐to‐first exacerbation may be a useful outcome to consider in future trials or review updates (or both), with the intervention effect expressed as a hazard ratio. As treatment regimens included in this review varied considerably, including for the same immunostimulant agent, it may be worthwhile conducting further trials comparing the effects of differing regimens for individual immunostimulant agents head‐to‐head in this patient subset. Further studies incorporating a cost–benefit analysis of immunostimulant therapies are also likely to be beneficial. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013343-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013343-sec-0008"></div> <div class="table" id="CD013343-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ immunostimulant vs. placebo for adults with chronic bronchitis or chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with chronic bronchitis or chronic obstructive pulmonary disease<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> immunostimulant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with immunostimulant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of participants with no exacerbations during the study period<br/>follow‐up: mean 6.1 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.48</b><br/>(1.15 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2961<br/>(15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants likely result in a slight increase in the number of participants with no exacerbations (or inversely, result in a reduction in the number of participants with ≥ 1 exacerbations). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b><br/>(6 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 100</b><br/>(71 to 80) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mortality (all‐cause)<br/>follow‐up: mean 8.4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.64</b><br/>(0.37 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1558<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>e,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants probably result in little to no difference in all‐cause mortality.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><br/>(8 to 23) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(22 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (respiratory‐related)<br/>follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b><br/>(1 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b><br/>(0.15 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>735<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunostimulants may result in little to no difference in respiratory‐related mortality.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/>assessed with: St George's Respiratory Questionnaire (SGRQ)<br/>Scale from: 0 to 100 <br/>follow‐up: mean 4.5 months<sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was <b>37.5</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>4.59 points lower</b><br/>(7.59 lower to 1.59 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>617<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>i,</sup><sup>j,</sup><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunostimulants may be associated with improvement in health‐related quality‐of‐life scores, but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of participants requiring antibiotics<br/>follow‐up: mean 6.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.34</b><br/>(0.18 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>542<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,</sup><sup>l,</sup><sup>m,</sup><sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants likely result in a reduction in the number of participants requiring antibiotics. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b><br/>(21 to 48) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b><br/>(33 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events/side effects<br/>follow‐up: mean 6.8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.01</b><br/>(0.84 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3780<br/>(20 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants do not increase the number of participants with an adverse event.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/>(5 to 7) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b><br/>(39 to 48) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429628585692116898" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429628585692116898</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The lowest and highest risk values are the second‐lowest and second‐highest proportions of participants with no exacerbations in the control groups from the studies included in this review. <br/><sup>b</sup> Risk of bias across most sectors for included studies was 'low' or 'unclear'. Exclusion of the studies in sensitivity analysis that were classified as 'high' risk of bias for attrition or selective reporting bias (or both) had little effect on the pooled effect estimate. No downgrade for risk of bias. <br/><sup>c</sup> Moderate clinical and statistical heterogeneity identified (I² = 53%). Heterogeneity could not be explained within subgroups. May partly be explained by variations in treatment regimens. Downgraded once.<br/><sup>d</sup> Funnel plot was asymmetrical, with several small studies demonstrating a positive effect (Figure 4). However, removal of the five smaller, positive studies by sensitivity analysis demonstrated no impact on the pooled estimate. Not downgraded. <br/><sup>e</sup> Study contributing the most weight in the analysis involved an elderly population with significant comorbidity, which may limit applicability of results to a general COPD/chronic bronchitis population. However, no impact on the pooled effect estimate when excluded in sensitivity analysis. No downgrade. <br/><sup>f</sup> Small number of events. Confidence intervals included the null effect and limited suggest that intervention may decrease or increase mortality. Downgraded once for imprecision.<br/><sup>g</sup> Study contributing the most weight in analysis involved an elderly population with significant comorbidity, which may limit applicability of results to a general COPD/chronic bronchitis population. Given there are only two studies in this meta‐analysis, downgraded once for indirectness.<br/><sup>h</sup> Lower score indicates better quality of life. <br/><sup>i</sup> One of two studies presented as abstract only and judged to be 'high' risk for attrition bias. Downgraded once for risk of bias. <br/><sup>j</sup> The minimally clinically important difference (MCID) for SGRQ is 4 points. The confidence interval did not include the null effect but the lower limit did not clear the MCID. Downgraded once for imprecision. <br/><sup>k</sup> Two studies included in meta‐analysis, from the same author groups. One study was presented as an abstract. Uncertain that there was a large enough body of evidence to affirm this as a true result. Downgraded once for risk of publication bias. <br/><sup>l</sup> Moderate clinical heterogeneity (I² = 38%) likely due to clinical and methodological diversity; however, uniform direction of effect estimate across individual studies. Downgraded once.<br/><sup>m</sup> One included study involved participants with COPD and 'borderline immune deficiency'. Exclusion of this study by sensitivity analysis did not have an effect on the pooled effect estimate. Not downgraded. <br/><sup>n</sup> Confidence interval limit for risk ratio crossed the 25% relative risk reduction threshold; however, did not include the null effect and optimal information size (OIS) criteria were met. Not downgraded. <br/><sup>o</sup> The confidence interval included the null effect, but the limits did not cross the 25% relative risk threshold for appreciable benefit or harm and OIS criteria were met. Not downgraded. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013343-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013343-sec-0009"></div> <section id="CD013343-sec-0010"> <h3 class="title" id="CD013343-sec-0010">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as "a common, preventable and treatable disease which is characterised by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases" (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Globally, COPD is a major cause of morbidity and mortality. In 2015, there was an estimated prevalence of 174 million cases, with three million deaths attributable to COPD (<a href="./references#CD013343-bbs2-0125" title="GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respiratory Medicine2017;5(9):691-706. [DOI: 10.1016/S2213-2600(17)30293-X]">GBD 2015</a>). Currently, COPD is considered the third leading cause of death worldwide (<a href="./references#CD013343-bbs2-0182" title="Global Health Estimates 2016: deaths by cause, age and sex, by country and by region, 2000–2016. www.who.int/healthinfo/global_burden_disease/estimates/en/ (accessed prior to 17 January 2019).">WHO GHE 2016</a>). These numbers are projected to increase further over the next 30 years due to a combination of population ageing and ongoing exposure to COPD risk factors (<a href="./references#CD013343-bbs2-0147" title="LopezAD , ShibuyaK , RaoC , MathersCD , HansellAL , HeldLS , et al. Chronic obstructive pulmonary disease: current burden and future projections. European Respiratory Journal2006;27(2):397-412. [DOI: 10.1183/09031936.06.00025805]">Lopez 2006</a>; <a href="./references#CD013343-bbs2-0181" title="World Health Organization. Projections of mortality and causes of death, 2016–2060. www.who.int/healthinfo/global_burden_disease/projections/en/ (accessed prior to 17 January 2019).">WHO 2018</a>). The economic burden associated with COPD is also substantial, with direct and indirect costs placing significant financial strain on individuals, their families, wider society, and healthcare systems worldwide (<a href="./references#CD013343-bbs2-0104" title="American Thoracic Society Foundation. The global burden of lung disease. foundation.thoracic.org/news/global-burden.php (accessed 26 December 2018).">ATS Foundation 2014</a>; <a href="./references#CD013343-bbs2-0136" title="JinjuvadiaC , JinjuvadiaR , MandapakalaC , DurairajanN , LiangpunsakulS , SoubaniAO . Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002–2010. COPD: Journal of Chronic Obstructive Pulmonary Disease2017;14(1):72-9. [DOI: 10.1080/15412555.2016.1199669]">Jinjuvadia 2017</a>). </p> <p>The symptoms of COPD include dyspnoea (breathlessness), chronic cough, and sputum production. COPD encompasses a range of clinical phenotypes, including emphysema and chronic bronchitis, with chronic bronchitis classically being defined as chronic cough and sputum production for at least three months per year for two consecutive years (<a href="./references#CD013343-bbs2-0124" title="FerrisBG . Epidemiology standardization project (American Thoracic Society). American Review of Respiratory Disease1978;118:1-120. [PMID: 742764]">Ferris 1978</a>). Alternative definitions of chronic bronchitis exist, including cough and phlegm almost every day or several times a week (<a href="./references#CD013343-bbs2-0142" title="KimV , CrapoJ , ZhaoH , JonesPW , SilvermanEK , ComellasA , et al. Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. Annals of the American Thoracic Society2015;12(3):332-9. [DOI: 10.1513/AnnalsATS.201411-518OC]">Kim 2015</a>). Whilst chronic bronchitis is not technically defined by airflow limitation, it may precede the development of this, and is still thought to be associated with airway disease and inflammation, an increased risk in the total number and severity of respiratory exacerbations, and functional limitations (<a href="./references#CD013343-bbs2-0141" title="KimV , HanMK , VanceGB , MakeBJ , NewellJD , HokansonJE . The chronic bronchitic phenotype of COPD: an analysis of the COPD Gene Study. Chest2011;140(3):626-33. [DOI: 10.1378/chest.10-2948]">Kim 2011</a>; <a href="./references#CD013343-bbs2-0184" title="WoodruffPG , BarrRG , BleeckerE , ChristensonSA , CouperD , CurtisJL , et al. Clinical significance of symptoms in smokers with preserved pulmonary function. New England Journal of Medicine2016;374(19):1811-21. [DOI: 10.1056/NEJMoa1505971]">Woodruff 2016</a>). </p> <p>A COPD exacerbation is defined as an acute worsening of respiratory symptoms that results in additional treatment (<a href="./references#CD013343-bbs2-0180" title="WedzichaJA , SeemungalTA . COPD exacerbations: defining their cause and prevention. Lancet2007;370(9589):786-96. [DOI: 10.1016/S0140-6736(07)61382-8]">Wedzicha 2007</a>). Exacerbations are often associated with increased airway inflammation, gas trapping, and mucous production (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>); these changes typically lead to symptoms of increased dyspnoea, alteration in sputum colour or volume, increased cough and wheeze, or a combination of these. Most COPD exacerbations are triggered by viral or bacterial respiratory infections (or both); however, environmental changes and air pollution may also play a role in either causing or worsening exacerbations (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>; <a href="./references#CD013343-bbs2-0183" title="WoodheadM , BlasiF , EwigS , GarauJ , HuchonG , IevenM , et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clinical Microbiology and Infection2011;17(6):E1-59. [DOI: 10.1111/j.1469-0691.2011.03672.x]">Woodhead 2011</a>). Studies have suggested that viruses are the causative pathogen in 34% to 56% of COPD exacerbations (<a href="./references#CD013343-bbs2-0151" title="MohanA , ChandraS , AgarwalD , GuleriaR , BroorS , GaurB , et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology2010;15(3):536-42. [DOI: 10.1111/j.1440-1843.2010.01722.x]">Mohan 2010</a>; <a href="./references#CD013343-bbs2-0159" title="PapiA , BellettatoCM , BraccioniF , RomagnoliM , CasolariP , CaramoriG , et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory and Critical Care Medicine2006;173(10):1114-21. [DOI: 10.1164/rccm.200506-859OC]">Papi 2006</a>; <a href="./references#CD013343-bbs2-0167" title="RohdeG , WiethegeA , BorgI , KauthM , BauerTT , GillissenA . Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax2003;58(1):37-42. [PMID: 12511718]">Rohde 2003</a>), with bacterial infections reportedly associated with up to 50% of exacerbations (<a href="./references#CD013343-bbs2-0159" title="PapiA , BellettatoCM , BraccioniF , RomagnoliM , CasolariP , CaramoriG , et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory and Critical Care Medicine2006;173(10):1114-21. [DOI: 10.1164/rccm.200506-859OC]">Papi 2006</a>). Additionally, viral and bacterial coinfection is common, and has been shown to correlate with an increased severity of exacerbations and longer duration of hospitalisation (<a href="./references#CD013343-bbs2-0159" title="PapiA , BellettatoCM , BraccioniF , RomagnoliM , CasolariP , CaramoriG , et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory and Critical Care Medicine2006;173(10):1114-21. [DOI: 10.1164/rccm.200506-859OC]">Papi 2006</a>; <a href="./references#CD013343-bbs2-0172" title="SinganayagamA , JoshiPV , MalliaP , JohnstonSL . Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Medicine2012;10:27. [DOI: 10.1186/1741-7015-10-27]">Singanayagam 2012</a>). </p> <p>It is widely known that respiratory exacerbations in COPD are associated with increased mortality, accelerated decline in lung function, increased hospitalisation and readmission rates, and decreased quality of life (<a href="./references#CD013343-bbs2-0139" title="KannerRE , AnthonisenNR , ConnettJE , Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. American Journal of Respiratory and Critical Care Medicine2001;164(3):358-64. [DOI: 10.1164/ajrccm.164.3.2010017]">Kanner 2001</a>; <a href="./references#CD013343-bbs2-0173" title="Soler-CataluñaJJ , Martínez-GarcíaMA , Román SánchezP , SalcedoE , NavarroM , OchandoR . Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax2005;60(11):925-31. [DOI: 10.1136/thx.2005.040527]">Soler‐Cataluña 2005</a>). In addition, a history of previous exacerbations is said to be the single biggest risk factor for future exacerbations (<a href="./references#CD013343-bbs2-0135" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MüllerovaH , Tal-SingerR , et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [DOI: 10.1056/NEJMoa0909883]">Hurst 2010</a>). Some people with COPD are more prone to frequent exacerbations (defined as two or more exacerbations per year) and this group has been shown to have worse outcomes and morbidity than those who experience less‐frequent exacerbations (<a href="./references#CD013343-bbs2-0171" title="SeemungalTA , DonaldsonGC , PaulEA , BestallJC , JeffriesDJ , WedzichaJA . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(5):1418-22. [DOI: 10.1164/ajrccm.157.5.9709032]">Seemungal 1998</a>). Aside from impacting the health status and prognosis of individuals, exacerbations also impose a significant socioeconomic burden on society, particularly those that necessitate hospital admission. </p> <p>A number of evidence‐based therapies exist to reduce symptoms and exacerbations, and improve lung function, exercise tolerance, and quality of life, in people with COPD. Key aspects of COPD management include smoking cessation, exercise, pulmonary rehabilitation, and regular vaccinations for both influenza and pneumococcal infections (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Other non‐pharmacological options for some people include treatment of hypoxaemia with long‐term oxygen therapy (<a href="./references#CD013343-bbs2-0117" title="CranstonJM , CrockettAJ , MossJR , AlpersJH . Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD001744. [DOI: 10.1002/14651858.CD001744.pub2]">Cranston 2005</a>), treatment of hypercapnia with long‐term non‐invasive ventilation (<a href="./references#CD013343-bbs2-0143" title="KöhnleinT , WindischW , KöhlerD , DrabikA , GeiselerJ , HartlS , et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respiratory Medicine2014;2(9):698-705. [DOI: 10.1016/S2213-2600(14)70153-5]">Köhnlein 2014</a>), and surgical or bronchoscopic lung volume reduction procedures (<a href="./references#CD013343-bbs2-0148" title="MarruchellaA , FaverioP , BonaitiG , PesciA . History of lung volume reduction procedures. Journal of Thoracic Disease2018;10:S3326-34. [DOI: 10.21037/jtd.2018.04.165]">Marruchella 2018</a>). Pharmacologically, the mainstay of treatment in stable COPD involves inhaled bronchodilators, including beta‐agonists and anti‐muscarinic agents (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>; <a href="./references#CD013343-bbs2-0140" title="KewKM , MavergamesC , WaltersJA . Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD010177. [DOI: 10.1002/14651858.CD010177.pub2]">Kew 2013</a>; <a href="./references#CD013343-bbs2-0177" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543-54. [DOI: 10.1056/NEJMoa0805800]">Tashkin 2008</a>). If people still have a high symptom or exacerbation burden, the addition of inhaled corticosteroids to a long‐acting beta‐agonist is recommended (<a href="./references#CD013343-bbs2-0154" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD006829. [DOI: 10.1002/14651858.CD006829.pub2]">Nannini 2012</a>). A number of oral anti‐inflammatory agents also reduce exacerbations in COPD, and are currently recommended for use in some people, including phosphodiesterase‐4 inhibitors, mucolytic agents, and macrolide antibiotics (<a href="./references#CD013343-bbs2-0112" title="ChongJ , LeungB , PooleP . Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD002309. [DOI: 10.1002/14651858.CD002309.pub4]">Chong 2013</a>; <a href="./references#CD013343-bbs2-0156" title="NiW , ShaoX , CaiX , WeiC , CuiJ , WangR , et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLOS One2015;10(3):e0121257. [DOI: 10.1371/journal.pone.0121257. eCollection 2015]">Ni 2015</a>; <a href="./references#CD013343-bbs2-0162" title="PooleP , ChongJ , CatesCJ . Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD001287. [DOI: 10.1002/14651858.CD001287.pub5]">Poole 2015</a>). </p> </section> <section id="CD013343-sec-0011"> <h3 class="title" id="CD013343-sec-0011">Description of the intervention</h3> <p>A glossary of the main immunological terms used is provided in <a href="./appendices#CD013343-sec-0086">Appendix 1</a>. </p> <p>The 2022 GOLD guidelines have specifically mentioned use of immunostimulant or immunoregulatory agents for preventing exacerbations in people with COPD (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Immunostimulants are defined as agents that create a state of non‐specific immunity and enhance the immune response towards infection or malignancy (<a href="./references#CD013343-bbs2-0132" title="HaddenJW . Immunostimulants. Trends in Pharmacological Sciences1993;14(5):169-74. [PMID: 8212312]">Hadden 1993</a>). They have existed for many years, and have long been suggested to have efficacy in preventing or reducing the severity of acute respiratory tract infections (ARTIs). </p> <p>In some countries, immunostimulants are regularly used for the prevention of ARTIs in children, and for reducing the frequency and severity of exacerbations in adults with COPD or chronic bronchitis (<a href="./references#CD013343-bbs2-0120" title="Del-Rio-NavarroBE , González-DíazS , Escalante-DomínguezAJ , Blandón-VijilV . Immunostimulants in the prevention of respiratory infections. International Journal of Biotechnology2007;9(3/4):246-60. [DOI: 10.1504/IJBT.2007.014245]">Del‐Rio‐Navarro 2007</a>). However, their widespread and routine use has been limited due to a shortage of high‐quality data regarding their efficacy, and a lack of understanding of their mechanisms of action and long‐term safety profiles. The 2022 GOLD guidelines acknowledge that, whilst older studies have demonstrated the efficacy of immunostimulants in reducing the severity and frequency of COPD exacerbations, further studies are needed to examine their effects in people who are receiving current 'gold‐standard' COPD maintenance therapy (<a href="./references#CD013343-bbs2-0114" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0146" title="LiJ , ZhengJP , YuanJP , ZengGQ , ZhongNS , LinCY . Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal2004;117(6):828-34. [PMID: 15198881]">Li 2004</a>). </p> <p>The immunostimulant agents that have been studied and used for the purpose of preventing ARTIs fall into three main categories: bacteria‐derived agents, synthetic agents, and thymic extracts (<a href="./references#CD013343-bbs2-0120" title="Del-Rio-NavarroBE , González-DíazS , Escalante-DomínguezAJ , Blandón-VijilV . Immunostimulants in the prevention of respiratory infections. International Journal of Biotechnology2007;9(3/4):246-60. [DOI: 10.1504/IJBT.2007.014245]">Del‐Rio‐Navarro 2007</a>). Most immunostimulants used in the prevention of ARTIs are orally or sublingually administered bacteria‐derived agents. These can be further categorised into those that are inactivated whole‐cell formulations, those that contain a mixture of antigenic fragments derived from several bacterial strains (bacterial lysates), and those that consist of a specific immunogenic component of a bacterium, such as ribosomal fractions or glycoproteins (<a href="./references#CD013343-bbs2-0110" title="CazzolaM , RoglianiP , CurradiG . Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respiratory Medicine2008;102(3):321-7. [DOI: 10.1016/j.rmed.2007.11.002]">Cazzola 2008</a>; <a href="./references#CD013343-bbs2-0120" title="Del-Rio-NavarroBE , González-DíazS , Escalante-DomínguezAJ , Blandón-VijilV . Immunostimulants in the prevention of respiratory infections. International Journal of Biotechnology2007;9(3/4):246-60. [DOI: 10.1504/IJBT.2007.014245]">Del‐Rio‐Navarro 2007</a>; <a href="./references#CD013343-bbs2-0126" title="GiovanniniM , SalviniF , RivaE . Bacterial extracts as immunomodulators for the prevention of recurrent respiratory infections in children. Journal of Medical Microbiology and Diagnosis2014;3:136. [DOI: 10.4172/2161-0703.1000136]">Giovannini 2014</a>). </p> <p>Bacterial lysates are composed of constituted fragments of bacterial antigens, obtained through the chemical or mechanical lysis (breakdown) of multiple inactivated bacterial strains that are commonly associated with respiratory infections, such as <i>Staphylococcus aureus</i> , <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , <i>Klebsiella pneumoniae</i> , <i>Moraxella catarrhalis</i> , <i>Streptococcus pyogenes</i> , and <i>Streptococcus viridans</i> (<a href="./references#CD013343-bbs2-0118" title="De BenedettoF , SevieriG . Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidisciplinary Respiratory Medicine2013;8(1):33. [DOI: 10.1186/2049-6958-8-33]">De Benedetto 2013</a>). </p> <p>The commercial availability of these agents varies by country, region, and clinical indication for use. As examples, a range of bacterial lysates have been approved for use for the prevention of recurrent respiratory tract infections in several European countries, including OM‐85, Ismigen, Ribomunyl, Lantigen B, and LW50020 (<a href="./references#CD013343-bbs2-0123" title="European Medicines Agency. Assessment report: bacterial lysates-containing medicinal products indicated for respiratory conditions. Published 28 June 2019. www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions (accessed prior to 12 June 2022).">EMA 2019</a>). OM‐85 is available and used across Central and South America for the treatment and prophylaxis of respiratory infections in children and adults (<a href="./references#CD013343-bbs2-0161" title="PivnioukV , PivnioukO , DeVriesA , UhrlaubJL , MichaelA , PivnioukD , et al. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. Journal of Allergy and Clinical Immunology2022;149(3):923-33.e6. [DOI: 10.1016/j.jaci.2021.11.019]">Pivniouk 2022</a>). In China, several immunostimulant agents are approved for use including OM‐85 and pidotimod (a synthetic immunostimulant agent) (<a href="./references#CD013343-bbs2-0113" title="Chinese Marketed Drug Database. Updated 28 March 2016. www.drugfuture.com/cndrug/ (accessed prior to 12 June 2022).">CMDD 2016</a>; <a href="./references#CD013343-bbs2-0161" title="PivnioukV , PivnioukO , DeVriesA , UhrlaubJL , MichaelA , PivnioukD , et al. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. Journal of Allergy and Clinical Immunology2022;149(3):923-33.e6. [DOI: 10.1016/j.jaci.2021.11.019]">Pivniouk 2022</a>). Conversely, immunostimulants are not currently approved for use in North America or Australasia.  </p> </section> <section id="CD013343-sec-0012"> <h3 class="title" id="CD013343-sec-0012">How the intervention might work</h3> <p>Immunostimulants used for the purpose of preventing respiratory tract infections in people with COPD or chronic bronchitis aim to heighten the host immune response against infective insults that may subsequently trigger an exacerbation. However, despite there being much research and knowledge gained about the effects of individual immunostimulatory agents on the immune system, the exact mechanism of action of both synthetic and bacteria‐derived agents at a molecular level is not completely understood (<a href="./references#CD013343-bbs2-0118" title="De BenedettoF , SevieriG . Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidisciplinary Respiratory Medicine2013;8(1):33. [DOI: 10.1186/2049-6958-8-33]">De Benedetto 2013</a>; <a href="./references#CD013343-bbs2-0120" title="Del-Rio-NavarroBE , González-DíazS , Escalante-DomínguezAJ , Blandón-VijilV . Immunostimulants in the prevention of respiratory infections. International Journal of Biotechnology2007;9(3/4):246-60. [DOI: 10.1504/IJBT.2007.014245]">Del‐Rio‐Navarro 2007</a>). </p> <p>OM‐85, a bacterial lysate derived by the chemical lysis of a number of the aforementioned bacterial strains, is thought to exert its effects through both cell‐mediated and humoral immune system pathways (<a href="./references#CD013343-bbs2-0118" title="De BenedettoF , SevieriG . Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidisciplinary Respiratory Medicine2013;8(1):33. [DOI: 10.1186/2049-6958-8-33]">De Benedetto 2013</a>; <a href="./references#CD013343-bbs2-0169" title="RozyA , Chorostowska-WynimkoJ . Bacterial immunostimulants – mechanism of action and clinical application in respiratory diseases. Advances in Respiratory Medicine2008;76(5):353-9. [PMID: 19003766]">Rozy 2008</a>). These include augmentation of the T helper cell lymphocyte (Th1) response (<a href="./references#CD013343-bbs2-0134" title="HuberM , MossmannM , BesslerWG . Th1-orientated immunological properties of the bacterial extract OM-85 BV. European Journal of Medical Research2005;10(5):209-17. [PMID: 15946922]">Huber 2005</a>), induction of specific immunoglobulin A antibody secretion by B lymphocyte cells (<a href="./references#CD013343-bbs2-0165" title="RialA , LensD , BetancorL , BenkielH , SilvaJS , ChabalgoityJA . Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses. Infection and Immunity2004;72(5):2679-88. [DOI: 10.1128/IAI.72.5.2679-2688.2004]">Rial 2004</a>; <a href="./references#CD013343-bbs2-0168" title="RossiGA , PeriC , RaynalME , DefilippiAC , RissoFM , SchenoneG , et al. Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunology Letters2003;86(1):85-91. [PMID: 12600750]">Rossi 2003</a>), direct activation of lung macrophages and monocytes (<a href="./references#CD013343-bbs2-0149" title="MauelJ , vanPhamT , KreisB , BauerJ . Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. International Journal of Immunopharmacology1989;11(6):637-45. [DOI: 10.1016/0192-0561(89)90149-5]">Mauel 1989</a>; <a href="./references#CD013343-bbs2-0169" title="RozyA , Chorostowska-WynimkoJ . Bacterial immunostimulants – mechanism of action and clinical application in respiratory diseases. Advances in Respiratory Medicine2008;76(5):353-9. [PMID: 19003766]">Rozy 2008</a>), upregulation of adhesion molecules (<a href="./references#CD013343-bbs2-0122" title="DuchowJ , MarchantA , DelvilleJP , SchandeneL , GoldmanM . Upregulation of adhesion molecules induced by Broncho-Vaxom® on phagocytic cells. International Journal of Immunopharmacology1992;14(5):761-6. [DOI: 10.1016/0192-0561(92)90073-T]">Duchow 1992</a>), and stimulation of phagocytic cell activity (<a href="./references#CD013343-bbs2-0169" title="RozyA , Chorostowska-WynimkoJ . Bacterial immunostimulants – mechanism of action and clinical application in respiratory diseases. Advances in Respiratory Medicine2008;76(5):353-9. [PMID: 19003766]">Rozy 2008</a>). It is thought that the immunostimulant components of OM‐85 bind to toll‐like receptors (TLRs), triggering signalling pathways that lead to activation and potentiation of the innate immune response (<a href="./references#CD013343-bbs2-0103" title="AlyanakianMA , GrelaF , AumeunierA , ChiavaroliC , GouarinC , BardelE , et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes2006;55(1):179-85. [DOI: 10.2337/diabetes.55.01.06.db05-0189]">Alyanakian 2006</a>; <a href="./references#CD013343-bbs2-0134" title="HuberM , MossmannM , BesslerWG . Th1-orientated immunological properties of the bacterial extract OM-85 BV. European Journal of Medical Research2005;10(5):209-17. [PMID: 15946922]">Huber 2005</a>; <a href="./references#CD013343-bbs2-0155" title="NavarroS , CossalterG , ChiavaroliC , KandaA , FleuryS , LazzariA , et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunology2011;4:53-65. [DOI: 10.1038/mi.2010.51]">Navarro 2011</a>; <a href="./references#CD013343-bbs2-0157" title="NikolovaM , StankulovaD , TaskovH , NenkovP , MaximovV , PetrunovB . Polybacterial immunomodulator respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections. International Immunopharmacology2009;9:425-32. [DOI: 10.1016/j.intimp.2009.01.004]">Nikolova 2009</a>). </p> <p>Mechanical bacterial lysates, specifically polyvalent mechanical bacterial lysates (PMBLs), have been demonstrated to stimulate dendritic cell maturation (<a href="./references#CD013343-bbs2-0153" title="MorandiB , AgazziA , D'AgostinoA , AntoniniF , CostaG , SabatiniF , et al. A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunology Letters2011;138(1):86-91. [DOI: 10.1016/j.imlet.2011.03.006]">Morandi 2011</a>), increase the number of circulating natural killer (NK) cells (<a href="./references#CD013343-bbs2-0145" title="LanzilliG , TraggiaiE , BraidoF , GarelliV , FolliC , ChiapporiA , et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: effects on circulating T, B and NK cells. Immunology Letters2013;149(1-2):62-7. [DOI: 10.1016/j.imlet.2012.11.009]">Lanzilli 2013</a>), increase specific immunoglobulin A antibody secretion by B cells, (<a href="./references#CD013343-bbs2-0168" title="RossiGA , PeriC , RaynalME , DefilippiAC , RissoFM , SchenoneG , et al. Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunology Letters2003;86(1):85-91. [PMID: 12600750]">Rossi 2003</a>), and activate both memory B lymphocytes and regulatory T lymphocytes (<a href="./references#CD013343-bbs2-0145" title="LanzilliG , TraggiaiE , BraidoF , GarelliV , FolliC , ChiapporiA , et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: effects on circulating T, B and NK cells. Immunology Letters2013;149(1-2):62-7. [DOI: 10.1016/j.imlet.2012.11.009]">Lanzilli 2013</a>). Studies have shown that the degree of the immune response created by the administration of mechanical bacterial lysates to patients directly correlates with positive clinical outcomes, such as reduced exacerbation frequency (<a href="./references#CD013343-bbs2-0109" title="BraidoF , SchenoneG , PallestriniE , ReggiardoG , CangemiG , CanonicaGW , et al. The relationship between mucosal immunoresponse and clinical outcome in patients with recurrent upper respiratory tract infections treated with a mechanical bacterial lysate. Journal of Biological Regulators and Homeostatic Agents2011;25(3):477-85. [PMID: 22023774]">Braido 2011</a>; <a href="./references#CD013343-bbs2-0144" title="LanzilliG , FalchettiR , CottarelliA , MacchiA , UngheriD , FuggettaMP . In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. International Journal of Immunopathology and Pharmacology2006;19(3):551-9. [DOI: 10.1177/039463200601900311]">Lanzilli 2006</a>; <a href="./references#CD013343-bbs2-0166" title="RicciR , PalmeroC , BazurroG , RiccioAM , GarelliV , Di MarcoE , et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulmonary Pharmacology and Therapeutics2014;27(1):109-13. [DOI: 10.1016/j.pupt.2013.05.006]">Ricci 2014</a>). </p> <p>Other bacterial extracts, made up of bacterial proteins or ribosomal fragments, also have specific immunomodulatory effects. For example, the immunostimulant RU41740 (Biostim), made up of <i>Klebsiella pneumoniae</i> glycoproteins and membrane fragments, activates macrophages, stimulates the B lymphocyte cell response (<a href="./references#CD013343-bbs2-0108" title="BoissierMC . Experimental immunopharmacology of RU 41740. La Presse Medicale1988;17(28):1426-9. [PMID: 2971179]">Boissier 1988</a>), and enhances antigen presentation (<a href="./references#CD013343-bbs2-0160" title="Pedraza-SánchezS , González-HernándezY , Escobar-GutiérrezA , RamachandraL . The immunostimulant RU41740 from Klebsiella pneumoniae activates human cells in whole blood to potentially stimulate innate and adaptive immune responses. International Immunopharmacology2006;6(4):635-46. [DOI: 10.1016/j.intimp.2005.10.006]">Pedraza‐Sánchez 2006</a>). Like bacterial lysates, RU41740 is thought to initiate an immune response through binding of its molecular components (such as lipopolysaccharide) to TLRs (<a href="./references#CD013343-bbs2-0150" title="MillerSI , ErnstRK , BaderMW . LPS, TLR4 and infectious disease diversity. Nature Reviews Microbiology2005;3(1):36-46. [DOI: 10.1038/nrmicro1068]">Miller 2005</a>). </p> <p>The immunostimulants containing thymic extracts also appear to interact with other TLRs and precursor T lymphocytes to increase dendritic cell, NK cell, and T cell activity, thus enhancing both innate and cell‐mediated immune responses (<a href="./references#CD013343-bbs2-0120" title="Del-Rio-NavarroBE , González-DíazS , Escalante-DomínguezAJ , Blandón-VijilV . Immunostimulants in the prevention of respiratory infections. International Journal of Biotechnology2007;9(3/4):246-60. [DOI: 10.1504/IJBT.2007.014245]">Del‐Rio‐Navarro 2007</a>; <a href="./references#CD013343-bbs2-0179" title="TuthillCW , KingRS . Thymosin alpha 1-A peptide immune modulator with a broad range of clinical applications. Journal of Clinical and Experimental Pharmacology2013;3:133. [DOI: 10.4172/2161-1459.1000133]">Tuthill 2013</a>). Synthetic immunostimulant compounds are reportedly better understood in terms of their molecular mechanism of action (<a href="./references#CD013343-bbs2-0120" title="Del-Rio-NavarroBE , González-DíazS , Escalante-DomínguezAJ , Blandón-VijilV . Immunostimulants in the prevention of respiratory infections. International Journal of Biotechnology2007;9(3/4):246-60. [DOI: 10.1504/IJBT.2007.014245]">Del‐Rio‐Navarro 2007</a>). Examples of synthetic immunostimulants include: tucaresol, which acts by promoting the interaction between antigen‐presenting cells and T cells (<a href="./references#CD013343-bbs2-0164" title="RhodesJ . Covalent chemical events in immune induction: fundamental and therapeutic aspects. Immunology Today1996;17(9):436-41. [DOI: 10.1016/0167-5699(96)10050-5Get]">Rhodes 1996</a>); imiquimod, which acts through TLR7 and TLR8 (<a href="./references#CD013343-bbs2-0174" title="SpanerDE , MillerRL , MenaJ , GrossmanL , SorrentiV , ShiY . Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leukemia and Lymphoma2005;46(6):935-9. [DOI: 10.1080/10428190500054426]">Spaner 2005</a>); and pidotimod, which acts by enhancing cell‐mediated immunity (<a href="./references#CD013343-bbs2-0106" title="BenettiGP , FugazzaL , StrambaBM , MontaltoF , BombelliG , La VecchiaG , et al. Ex vivo evaluation of pidotimod activity on cell-mediated immunity. Drug Research1994;44(12A):1476-9. [PMID: 7857346]">Benetti 1994</a>). </p> <p>A number of trials and systematic reviews have analysed the use of immunostimulant in preventing ARTIs in children and adults, and in preventing exacerbations in adults with chronic bronchitis or COPD. One previous Cochrane Review evaluated immunostimulants for preventing respiratory tract infections in children. The review authors included 34 placebo‐controlled trials, and reported that immunostimulants were associated with approximately 40% fewer acute respiratory infections compared with placebo. However, they also commented that "trial quality was generally poor and a high level of statistical heterogeneity was evident" (<a href="./references#CD013343-bbs2-0121" title="Del-Rio-NavarroBE , Espinosa RosalesF , FlenadyV , Sienra-MongeJJ . Immunostimulants for preventing respiratory tract infection in children. Evidence Based Child Health2012;7(2):629-717. [DOI: 10.1002/ebch.1833]">Del‐Rio‐Navarro 2012</a>). One meta‐analysis examining the efficacy of PMBLs in preventing respiratory tract infections in children and adults looked at data across 15 randomised controlled trials. Treatment with PMBLs was associated with a significant reduction in respiratory infections compared with placebo (<a href="./references#CD013343-bbs2-0111" title="CazzolaM , AnapurapuS , PageCP . Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulmonary Pharmacology and Therapeutics2012;25(1):62-8. [DOI: 10.1016/j.pupt.2011.11.002]">Cazzola 2012</a>). </p> <p>One systematic review found that the bacterial extracts OM‐85, LW‐50020, and SL‐04 were associated with improved symptoms in people with COPD, chronic bronchitis, or both, and the meta‐analysis suggested a lessened exacerbation duration. However, there was no evidence of a difference between the extracts and placebo in preventing exacerbations (<a href="./references#CD013343-bbs2-0176" title="Steurer-SteyC , BachmannLM , SteurerJ , TramèrMR . Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest2004;126(5):1645-55. [10.1378/chest.126.5.1645]">Steurer‐Stey 2004</a>). Another systematic review examined the efficacy of OM‐85 in preventing exacerbations in people with COPD or chronic bronchitis (or both). There was a non‐significant trend in favour of OM‐85; however, benefit was not clearly demonstrated across a range of important clinical outcomes (<a href="./references#CD013343-bbs2-0175" title="SprenkleMD , NiewoehnerDE , MacDonaldR , RutksI , WiltTJ . Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD: Journal of Chronic Obstructive Pulmonary Disease2005;2(1):167-75. [PMID: 17136978]">Sprenkle 2005</a>). In 2015, one meta‐analysis and systematic review examined the effects of OM‐85 in people with COPD on exacerbation rate, in addition to several other minor clinical end points. OM‐85 was associated with a 20% reduction in exacerbation rate and 39% reduction in the incidence rate of people using antibiotics compared with placebo (<a href="./references#CD013343-bbs2-0158" title="PanL , JiangXG , GuoJ , TianY , LiuCT . Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of Clinical Pharmacology2015;55(10):1086-92. [DOI: 10.1002/jcph.518]">Pan 2015</a>). However, the authors concluded that there was insufficient evidence to support the routine use of OM‐85 in people with COPD, suggesting that further larger‐scale trials needed to be undertaken. </p> <p>The cost‐effectiveness of the immunostimulant OM‐85 for preventing respiratory exacerbations in adults with COPD or chronic bronchitis (or both) has previously been examined. Prospective cost‐effectiveness and cost–benefit analyses were conducted alongside a randomised controlled trial comparing OM‐85 to placebo in adults with COPD (<a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>). Authors found that its use was associated with a reduction in the direct and indirect costs of a severe exacerbation warranting hospitalisation (<a href="./references#CD013343-bbs2-0115" title="ColletJP , DucruetT , HaiderS , ShapiroS , RobinsonA , RenziPM , et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Canadian Respiratory Journal2001;8(1):27-33. [DOI: 10.1155/2001/508015]">Collet 2001</a>). Other studies have also found that OM‐85 appears to be cost‐effective for the prevention of acute respiratory exacerbations in adults with chronic bronchitis (<a href="./references#CD013343-bbs2-0107" title="BergemannR , BrandtA , ZoellnerU , DonnerCF . Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis. Archivio Monaldi per le Malattie del Torace1994;49(4):302-7. [PMID: 8000415]">Bergemann 1994</a>; <a href="./references#CD013343-bbs2-0185" title="XuanJ , WangL , YinH , XuanD , ZhouY , HuS . The cost-effectiveness of OM-85 in managing respiratory tract infections in China. Journal of Medical Economics2015;18(3):167-72. [DOI: 10.3111/13696998.2014.971159]">Xuan 2014</a>). </p> </section> <section id="CD013343-sec-0013"> <h3 class="title" id="CD013343-sec-0013">Why it is important to do this review</h3> <p>Immunostimulant agents in COPD or chronic bronchitis could theoretically enhance non‐specific immunity against a number of respiratory insults, which is an important concept given the number of pathogens, including myriad viruses, that can precipitate an exacerbation. However, the use of immunostimulants in this population thus far has been controversial. This is largely due to concerns about quantity and quality of evidence in the past, a lack of understanding of their long‐term effects, and existing uncertainty around their exact mechanisms of action. As mentioned, GOLD guidelines recognise that some older studies have reported a decrease in the severity and frequency of COPD exacerbations, but more trials are needed in people receiving currently recommended maintenance therapy (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Overall, there have been mixed results from previous trials and systematic reviews regarding clinical efficacy of immunostimulants in adults with COPD or chronic bronchitis; many have reported positive impacts on exacerbation rates (or a trend towards this) and other clinically relevant outcomes, but have been unable to suggest an overall benefit in these patients due to limited availability of data, poor trial quality, or both. </p> <p>This systematic review aims to critically appraise all available data regarding the efficacy and use of immunostimulants as a preventive therapy in adults with stable COPD or chronic bronchitis (or both). This may help to further understand their clinical value and safety, and may highlight areas requiring further research and development. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013343-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013343-sec-0014"></div> <p>To determine the efficacy of immunostimulants in preventing respiratory exacerbations in adults with chronic obstructive pulmonary disease, chronic bronchitis, or both. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013343-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013343-sec-0015"></div> <section id="CD013343-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013343-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel randomised controlled trials (RCTs) comparing immunostimulant therapy, administered by any route, with placebo. We included studies reported in full text, those published as an abstract only, and unpublished data. We excluded cross‐over trials due to the nature of COPD as a progressive disease and due to the possibility of a carry‐over effect from the first treatment period. However, if these studies presented separate comparison data prior to any cross‐over occurring then this data set was considered for review inclusion. </p> </section> <section id="CD013343-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (older than 18 years of age) with a diagnosis of COPD (defined by a postbronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio less than 0.7) or chronic bronchitis (defined by either the classic definition of chronic cough and sputum production for at least three months per year for two consecutive years (<a href="./references#CD013343-bbs2-0124" title="FerrisBG . Epidemiology standardization project (American Thoracic Society). American Review of Respiratory Disease1978;118:1-120. [PMID: 742764]">Ferris 1978</a>), or alternative definitions such as cough and phlegm almost every day or several times a week (<a href="./references#CD013343-bbs2-0142" title="KimV , CrapoJ , ZhaoH , JonesPW , SilvermanEK , ComellasA , et al. Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. Annals of the American Thoracic Society2015;12(3):332-9. [DOI: 10.1513/AnnalsATS.201411-518OC]">Kim 2015</a>)), or both COPD and chronic bronchitis. An underlying principle was that study participants met well‐established criteria at the time, whether for COPD or chronic bronchitis. </p> <p>We excluded studies of participants with asthma, bronchiectasis, or genetic/other lung conditions that predispose or lead to chronic airflow obstruction, such as cystic fibrosis, or people with known specific immunodeficiencies. However, if a study included these types of participants and additionally included people with COPD or chronic bronchitis (or both), we analysed data for these subsets of participants if presented separately. </p> </section> <section id="CD013343-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Participants must have received immunostimulant therapy or placebo, administered by any route (oral, sublingual, subcutaneous, or intravenous), for at least one month. Where a study involved an intermittent dosing regimen, in which the cumulative treatment days totalled less than one month, but the overall treatment duration was at least one month, we elected to include this study in the review. </p> <p>We excluded studies of specific immunostimulants, such as influenza or pneumococcal vaccines, immunotherapy used to treat cancer (either directly, or the immune deficiency resulting from chemotherapy), allergic disease, and treatment to replace immunoglobulins in known specific immune deficiency disorders. We excluded trials referring to vitamins, nutritional supplements, herbal extracts, or homeopathic remedies. We excluded studies that focussed on the treatment of acute exacerbations with immunostimulants (as opposed to prevention and prophylaxis). We did not consider studies that focussed on improvement in immunological parameters as the sole outcome. </p> </section> <section id="CD013343-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We only included studies where the primary outcomes were measured for at least 12 weeks. </p> <p>Reporting of one or more of the listed outcomes was not an inclusion criterion for the review. </p> <p>Exacerbations were chosen as the primary outcome as immunostimulant therapy is most commonly administered as a preventive therapy, and thus far exacerbations have represented the main clinically relevant end point used for efficacy of immunostimulant agents and many other anti‐inflammatory drugs used in COPD or chronic bronchitis (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). As mentioned, exacerbations significantly affect patient morbidity and mortality and have a significant impact on overall disease burden; therefore, we considered that exacerbations and mortality were important as primary outcomes in this review. </p> <section id="CD013343-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013343-list-0001"> <li> <p>Number of participants with no exacerbations during the study period.</p> </li> <li> <p>Mortality (all‐cause).</p> </li> </ul> </p> <p>There was considerable variability in the degree of reporting and description of what constituted a respiratory exacerbation between included studies; hence, we accepted the study authors' definition of an exacerbation. </p> <p>As outlined in our review protocol (<a href="./references#CD013343-bbs2-0186" title="FraserA , PooleP . Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2019, Issue 5. Art. No: CD013343. [DOI: 10.1002/14651858.CD013343]">Fraser 2019</a>), we had intended to look at and delineate the number of participants with exacerbations of COPD or chronic bronchitis (or both) that would be considered moderate or severe in accordance with GOLD criteria definitions (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>), and use this information to inform our primary outcomes along with all‐cause mortality. However, following the data extraction process and prior to performing any statistical analysis, it was apparent that these outcomes could not be determined from the information and data presented in the included studies.  </p> <p>In order to allow us to combine and interpret our review outcomes, a deviation from our original intended primary outcomes was considered necessary. Therefore, we chose the dichotomous outcome of 'number of participants with no exacerbations during the study period.' </p> </section> <section id="CD013343-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013343-list-0002"> <li> <p>Mortality (respiratory‐related).</p> </li> <li> <p>Quality of life (participant‐reported, measured by a validated scale, such as the St George's Respiratory Questionnaire (SGRQ) (<a href="./references#CD013343-bbs2-0137" title="JonesPW , QuirkFH , BaveystockCM , LittlejohnsP . A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. American Review of Respiratory Disease1992;145(6):1321-7.">Jones 1992</a>) or Chronic Respiratory Diseases Questionnaire (CRQ) (<a href="./references#CD013343-bbs2-0131" title="GuyattGH , BermanLB , TownsendM , PugsleySO , ChambersLW . A measure of quality of life for clinical trials in chronic lung disease. Thorax1987;42(10):773-8. [PMID: 3321537]">Guyatt 1987</a>)). </p> </li> <li> <p>Number of participants requiring antibiotics.</p> </li> <li> <p>Exacerbation duration.</p> </li> <li> <p>Hospitalisation duration (respiratory‐related).</p> </li> <li> <p>Adverse events/side effects.</p> </li> </ul> </p> <p>The secondary outcomes are other important measures of the efficacy and safety of immunostimulant agents.  </p> <p>Our protocol outlined our intentions to include the 'total number of exacerbations' as a secondary outcome; however, including this was no longer necessary given the reformulation of the primary outcomes that would capture this information. Analysing exacerbation duration was considered to provide indirect information regarding the potential socioeconomic and quality‐of‐life impacts of the intervention. Quality‐of‐life assessments highlight information regarding the impact of the intervention on the objective and subjective wellbeing of the patient, and are an important outcome in any chronic disease. Given that little is understood about the long‐term safety of these agents and concerns around this have previously limited recommendation for widespread use, adverse events were included as a secondary outcome for this review. </p> <p>We added 'Number of participants requiring antibiotics' and 'hospitalisation duration (respiratory‐related)' as secondary outcome measures following data extraction and prior to data synthesis occurring. These were metrics reported in several included studies, and were considered surrogate markers of exacerbation severity in lieu of being able to obtain clear data around how many of the exacerbations could be considered 'moderate' or 'severe' (or both) by GOLD definitions (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Several studies reported 'Antibiotic duration'; however, we considered that a dichotomous outcome regarding antibiotic use would be more statistically robust. Conversely, the 'number of participants requiring hospitalisation' was rarely reported, and inclusion as an outcome would have contributed little to overall comparison. </p> </section> </section> </section> <section id="CD013343-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013343-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified studies from searches of the following databases and trial registries:</p> <p> <ul id="CD013343-list-0003"> <li> <p>Cochrane Airways Trials Register (<a href="https://airways.cochrane.org/trials-register" target="_blank">airways.cochrane.org/trials-register</a>), via the Cochrane Register of Studies, all years to 25 January 2022; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), via the Cochrane Register of Studies, all years to 25 January 2022; </p> </li> <li> <p>MEDLINE (OvidSP) ALL 1946 to 25 January 2022;</p> </li> <li> <p>Embase (OvidSP) 1974 to 25 January 2022;</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ul> </p> <p>The database search strategies are detailed in <a href="./appendices#CD013343-sec-0087">Appendix 2</a>. The Cochrane Airways Information Specialist in collaboration with the review authors wrote the search strategies and executed the searches. </p> <p>We searched all databases and trials registries from their inception to 25 January 2022, with no restrictions on language or type of publication. We handsearched conference abstracts and grey literature identified through the Cochrane Airways Trials Register and the CENTRAL database. </p> </section> <section id="CD013343-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for study information. </p> </section> </section> <section id="CD013343-sec-0026"> <h3 class="title" id="CD013343-sec-0026">Data collection and analysis</h3> <section id="CD013343-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We used Cochrane's Screen4Me workflow to help assess the search results.  Screen4Me comprises three components: known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as an RCT or as Not an RCT; the RCT classifier – a machine learning model that distinguishes RCTs from non‐RCTs, and if appropriate, Cochrane Crowd – Cochrane's citizen science platform where the Crowd help to identify and describe health evidence (<a href="./references#CD013343-bbs2-0178" title="ThomasJ , McDonaldS , Noel-StorrA , ShemiltI , ElliottJ , MavergamesC , et al. Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews. Journal of Clinical Epidemiology2020;133:140-51. [PMID: 33171275]">Thomas 2020</a>). We used the first two components. </p> <p>Following this initial assessment, two review authors (AF and PP) independently screened the titles and abstracts of the search results and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve.' We retrieved the full‐text study reports of all potentially eligible studies and two review authors (AF and PP) independently screened them for inclusion, recording the reasons for exclusion of ineligible studies. Where we could not obtain the full‐text study reports, we marked these studies as 'awaiting classification.' We resolved any disagreements through discussion. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. Seventeen translators reviewed papers published in languages other than English; if studies met initial screening criteria and were subsequently marked for inclusion, the translators completed formal data extraction sheets for individual studies.  We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD013343-bbs2-0152" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]">Moher 2009</a>), and documented justification for each study exclusion (see <a href="./references#CD013343-sec-0098" title="">Characteristics of excluded studies</a> table and <a href="#CD013343-sec-0053">Excluded studies</a>).  </p> </section> <section id="CD013343-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted and collated data using the online software tool Covidence (<a href="./references#CD013343-bbs2-0116" title="Covidence. Melbourne, Australia: Veritas Health Innovation, (accessed prior to 1 September 2022). Available at covidence.org.">Covidence</a>), and exported online data extraction forms for individual studies to Excel worksheets. We extracted the following study characteristics from included studies using the Covidence data extraction process as a template. </p> <p> <ul id="CD013343-list-0004"> <li> <p>Methods: study design, total duration of study, number of study centres and location, study setting, date of study. </p> </li> <li> <p>Participants: number (n), mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, baseline exacerbation frequency, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, dosing regimen, type of compound, route of administration, duration of therapy. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for studies and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (AF and PP) independently extracted outcome data from included studies. These data were then cross‐checked between the two review authors and a consensus decision reached by discussion for each included study. We extracted data if it was deemed to be potentially relevant to protocol‐specified outcomes; the <a href="./references#CD013343-sec-0097" title="">Characteristics of included studies</a> table and <a href="#CD013343-tbl-0002">Table 1</a> identify the reported study outcomes for which we extracted data. One review author (AF) transferred data into the Review Manager 5 (<a href="./references#CD013343-bbs2-0163" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), and double‐checked data against the data presented within the original study reports. The second review author (PP) spot‐checked study characteristics for accuracy against the study report. </p> <div class="table" id="CD013343-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study duration (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participant type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Presence of acute exacerbation as an inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (total duration)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relevant outcomes measured</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3 </p> <p>1 g 3 times daily (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, SGRQ score, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3 </p> <p>3 g daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SGRQ score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> <p>(data extracted limited to COPD patient subset)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740 (Biostim)</p> <p>2 mg daily for 8 consecutive days in first month; 1 mg daily for 8 consecutive days in second/third months (3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, exacerbation duration, number of participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pidotimod </p> <p>800 mg daily (2 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> <p>(asthma patient subset excluded from analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D53 (Ribomunyl)</p> <p>4 sequences of 15 days of aerosol treatment separated by 1‐week intervals. Subcutaneous injections days 7 and 14 of first sequence and day 14 of following sequences (2.7 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol and subcutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, participants with no or a reduction in antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740 (Biostim)</p> <p>2 mg daily or 8 mg daily (2 intervention groups) for 1 week, alternate weeks (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, exacerbation duration, duration of antibiotic therapy, AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3 </p> <p>500 mg 3 times daily (4 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, number of exacerbations, exacerbation duration, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ismigen</p> <p>50 mg daily for 10 consecutive days/month for 3 months, then 3 months without treatment, then repeat of the initial regimen (9 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyvalent mechanical bacterial lysate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, exacerbation rate, days to first exacerbation, hospitalisation days (respiratory and all‐cause), participants requiring concomitant medications, QoL scale scores, AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3</p> <p>500 mg 3 times daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD plus "cell‐mediated immune deficiency"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymomodulin </p> <p>60 mg twice daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, QoL scale scores, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ismigen</p> <p>50 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyvalent mechanical bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, exacerbation duration, duration of antibiotic therapy, hospitalisation rate (respiratory), hospitalisation duration (respiratory), hospitalisation days (respiratory), AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pidotimod</p> <p>800 mg daily (2 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, days to first exacerbation, exacerbation duration, duration of antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85 </p> <p>7 mg daily for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (4 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, hospitalisation rate (respiratory and all‐cause), participants requiring hospitalisation (respiratory and all‐cause), hospitalisation duration (respiratory), hospitalisation days (respiratory and all‐cause), mean number of hospital days per participant (respiratory), change in SF‐36 scale scores, AEs, mortality (respiratory and all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation duration, total exacerbation days, participants requiring antibiotics, participants requiring bronchodilator therapy, FEV1, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, participants requiring antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB plus "borderline immune deficiency"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lantigen B (2 intervention groups)</p> <p>15 drops twice daily for 1 month, then 1 month without treatment, then a 15 days of initial regimen (2.5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sublingual </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, duration of concomitant therapy, FEV1 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, exacerbation duration, days to first exacerbation, duration of concomitant therapy, hospitalisation rate and duration (all‐cause), SGRQ scores, FEV1, AEs/serious AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740 (Biostim)</p> <p>2 mg daily for 8 consecutive days in first month; 1 mg daily for 8 consecutive days in second/third months (3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, exacerbation duration, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0020" title="FoschinoBM , RestaO , CassanoA , AltieriA , GuidoP , PitiA , et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants. Minerva Pneumologica1995;34(2):39-44. ">Foschino 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D53 (Ribomunyl)</p> <p>1 tablet (dose not specified) daily for 4 consecutive days/week for 3 weeks, then 1 tablet daily for 4 consecutive days/month for 5 months (5.75 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symbioflor</p> <p>30 drops 3 times daily (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral vs sublingual (liquid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, days to first exacerbation, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation duration, duration of antibiotic therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations, duration of antibiotic therapy, duration of corticosteroid therapy, hospitalisation rate (respiratory) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0024" title="LiJ , ZhengJP , YuanJP , YangL , LuoDF , AnJY , et al. Protection of oral immunostimulant bronchovaxom against with chronic obstructive pulmonary disease. Respirology2005;10(3):A137. LiJ , ZhengJP , YuanJP , ZengGQ , ZhongNS , LinCY . Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal2004;117(6):828-34. ">Li 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, duration of antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diribiotine CK</p> <p>10 mL daily for 20 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral (liquid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, exacerbation duration, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, exacerbation duration, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, mean number of antibiotic courses, participants requiring bronchodilator therapy, participants requiring corticosteroids, AEs, mortality (respiratory and all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (4 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, hospitalisation duration (respiratory), mean number of hospitalisations per participant (respiratory), AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymomodulin</p> <p>80 mg 3 times daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, hospitalisation duration (all‐cause), mean number of concomitant medication courses, duration of concomitant therapies, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0031" title="RochemaureJ , LehertP , SauvagetJ , RobillardM , Betbeder-MatibetA . Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis. Revue de Pneumologie Clinique1988;44(1):43-7. RochemaureJ , LehertP , SauvagetJ , RobillardM , MurrayN , CastanierJC . Usefulness of immunomodulating agents. Lancet1987;2(8559):101. ">Rochemaure 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diribiotine CK</p> <p>10 mL daily for 20 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral (liquid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, mean number of antibiotic courses, duration of antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, number of exacerbations, participants requiring concomitant medication, AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, duration of antibiotic therapy, duration of bronchodilator therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, participants requiring concomitant medication, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyaluronan</p> <p>7.5 mg subcutaneously weekly (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, total exacerbation days, total antibiotic days, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations, exacerbation duration, participants requiring antibiotics, participants requiring bronchodilator therapy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse events; CB: chronic bronchitis; COPD: chronic obstructive pulmonary disease; QoL: quality of life; SF‐36: 36‐item Short Form Survey; SGRQ: St George's Respiratory Questionnaire.<br/><sup>a</sup>Total n: number of participants for whom outcome data were available. </p> </div> </div> </section> <section id="CD013343-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AF and PP) independently assessed risk of bias for each study using the RoB 1 tool for RCTs according to criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013343-bbs2-0133" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved any disagreements by discussion. We assessed risk of bias according to the following domains. </p> <p> <ul id="CD013343-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We judged each potential source of bias as high, low, or unclear, and provided a quote where relevant from the study report together with a justification for our judgement. We summarised the risk of bias judgements across different studies for each of the domains listed. When assessing attrition bias, we used an approximate cut‐off of 20% dropout for 'high' risk; however, the type of analysis performed (e.g. intention‐to‐treat (ITT)), the balance between trial arms, and reasons given for dropout were also taken into account. When considering treatment effects, we considered the risk of bias for the studies that contributed to that outcome. </p> <section id="CD013343-sec-0030"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>Generally, we conducted the review in accordance with the published protocol (<a href="./references#CD013343-bbs2-0186" title="FraserA , PooleP . Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2019, Issue 5. Art. No: CD013343. [DOI: 10.1002/14651858.CD013343]">Fraser 2019</a>). We reported and justified deviations from the protocol in the <a href="#CD013343-sec-0095">Differences between protocol and review</a> section of the review. </p> </section> </section> <section id="CD013343-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs) with a 95% confidence interval (CI), and continuous data as mean differences (MD) with a 95% CI. For dichotomous outcomes, we intended to calculate the number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH). </p> <p>Meta‐analyses were undertaken only where this was meaningful; that is, if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>We planned to describe skewed data narratively (e.g. as medians and interquartile ranges for each group).  </p> <p>Where multiple trial arms were reported in a single study, we included only the relevant arms. All treatment arms are specified in the <a href="#CD013343-sec-0043">Included studies</a> section and <a href="#CD013343-tbl-0002">Table 1</a>. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we combined the active arms. </p> <p>Several studies reported outcomes measured over discrete time intervals. Where this occurred, and the outcome was measured over a period of less than 12 weeks, we excluded these data from a meta‐analysis. If the data were analysed over at least 12 weeks, we elected to include the data that had been measured from the commencement of the study in a meta‐analysis (i.e. from baseline, as opposed to from a later time point within the study). This earlier period was chosen as it was considered to best encapsulate participants who were truly randomised, with no likelihood of a carry‐over treatment effect from earlier in the study potentially affecting outcome measures. The results from later time intervals of the relevant studies, whilst not included in meta‐analyses, are discussed within the text of the review. </p> <p>We used the difference between end point scores for studies that reported quality of life using a validated scale.  </p> <p>We used ITT or 'full analysis set' analyses where they were reported (i.e. those where data had been imputed for participants who were randomly assigned but did not complete the study), instead of completer or per‐protocol analyses. </p> </section> <section id="CD013343-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants, rather than events, as the unit of analysis (e.g. the number of participants with an exacerbation, rather than the number of exacerbations per participant). We avoided treating count data as dichotomous data to avoid unit‐of‐analysis error in recurring events. </p> </section> <section id="CD013343-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>When missing data were thought to introduce serious bias, this was taken into consideration in the GRADE rating for affected outcomes. </p> <p>We recorded any assumptions made around the reason or nature of missing data within the review. We performed sensitivity analyses to assess how variable the results may have been to any assumptions made about missing data. </p> </section> <section id="CD013343-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity among the studies in each analysis. Where there was substantial heterogeneity, we explored possible causes by performing prespecified subgroup analyses. As per Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013343-bbs2-0119" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. In: Available from training.cochrane.org/handbook.">Deeks 2022</a>), we considered the following ranges for assessing heterogeneity. </p> <p> <ul id="CD013343-list-0006"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: may show considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD013343-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>When we were able to pool more than 10 studies, we created and examined a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD013343-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model. Sensitivity analyses were performed using a fixed‐effect model. </p> </section> <section id="CD013343-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were performed based on measures of disease severity (baseline FEV1 and exacerbation frequency). </p> <p>Most studies that reported the primary outcomes included orally delivered immunostimulant agents, with only two studies analysing sublingually  and subcutaneously delivered immunostimulants. Therefore, we considered it less relevant to include 'mode of delivery' as a subgroup, as originally outlined in our protocol (<a href="./references#CD013343-bbs2-0186" title="FraserA , PooleP . Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2019, Issue 5. Art. No: CD013343. [DOI: 10.1002/14651858.CD013343]">Fraser 2019</a>). We considered further differentiation of the immunostimulant agents based on dose and treatment regimen; however, there was much variability between studies limiting the ability to subgroup by these categories. Therefore, we only performed subgroup analyses based on the immunostimulant type. </p> <p>Because of the variation seen in treatment course lengths and follow‐up periods across all studies, we used the point of longest follow‐up for assessment of outcomes overall, and added subgroup analyses following the data extraction phase to investigate for heterogeneity that may have been explained by treatment or overall study duration (or both). </p> <p>We made these above alterations by consensus discussion following data extraction, but prior to any data synthesis and analysis occurring. </p> <p>We performed the following subgroup analyses.</p> <p> <ul id="CD013343-list-0007"> <li> <p>Type of immunostimulant agent.</p> </li> <li> <p>Severity of COPD based on lung function testing: mild or moderate (defined by FEV1 50% or greater predicted) versus severe or very severe (FEV1 less than 50% predicted) (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). </p> </li> <li> <p>Mean baseline exacerbation rate two or more in the preceding year versus fewer than two in the preceding year or unspecified. </p> </li> <li> <p>Treatment duration (three months or less versus greater than three months).</p> </li> <li> <p>Study duration (three to less than six months versus six months to less than 12 months versus 12 months or greater). </p> </li> </ul> </p> <p>We used the following outcomes in subgroup analyses.</p> <p> <ul id="CD013343-list-0008"> <li> <p>Number of participants with no exacerbations during the study period.</p> </li> <li> <p>Mortality (all‐cause).</p> </li> </ul> </p> <p>We used the formal test for subgroup interactions in Review Manager 5 (<a href="./references#CD013343-bbs2-0163" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD013343-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out the following sensitivity analyses, removing from the primary outcome analyses: </p> <p> <ul id="CD013343-list-0009"> <li> <p>trials judged in the risk of bias table at high risk of bias for any of the six domains;</p> </li> <li> <p>trials where decisions or assumptions had been made around missing data.</p> </li> </ul> </p> <p>We compared the results from a fixed‐effect model with the random‐effects model.</p> </section> <section id="CD013343-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The summary of findings table contained the following outcomes.</p> <p> <ul id="CD013343-list-0010"> <li> <p>Number of participants with no exacerbations during the study period.</p> </li> <li> <p>Mortality (all‐cause).</p> </li> <li> <p>Mortality (respiratory‐related).</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Number of participants requiring antibiotics.</p> </li> <li> <p>Adverse events/side effects.</p> </li> </ul> </p> <p>We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data for the prespecified outcomes. We used the methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013343-bbs2-0170" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>), using GRADEpro GDT software (<a href="./references#CD013343-bbs2-0129" title="GRADEpro GDT. Version accessed prior to 17 January 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We outlined all decisions to downgrade the certainty of the evidence using footnotes and comments to aid in readers' understanding of the review.  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013343-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013343-sec-0040"></div> <section id="CD013343-sec-0041"> <h3 class="title">Description of studies</h3> <p>This review is based on a published protocol (<a href="./references#CD013343-bbs2-0186" title="FraserA , PooleP . Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2019, Issue 5. Art. No: CD013343. [DOI: 10.1002/14651858.CD013343]">Fraser 2019</a>). </p> <section id="CD013343-sec-0042"> <h4 class="title">Results of the search</h4> <p>For details of the search history, see <a href="./appendices#CD013343-sec-0087">Appendix 2</a>, and for the PRISMA study flow diagram, see <a href="#CD013343-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013343-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013343-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Following deduplication, the database and trial registry searches run on 24 May 2019 and 25 January 2022 retrieved 1037 references, and searches of included study and related systematic review reference lists identified a further 13 records (totalling 1050 references). The original 1037 references were additionally screened by Cochrane's Screen4Me services, which analyses and removes references from the results set before the manual screening stage using the Classifier and known assessments, and this process excluded 481 references. We then manually screened the 569 remaining records, excluding 435 on the basis of title and abstract, removing one by manual deduplication, and marking 133 for full‐text review. For five of these references, abstracts or full text (or both) were unobtainable through local library and Cochrane interlibrary loan requests, and have been marked as 'awaiting classification' (see <a href="./references#CD013343-bbs1-0003" title="">Studies awaiting classification</a>). Therefore, 128 studies underwent full‐text screening. Following manual deduplication and grouping of multiple study reports with the primary reference, we excluded a further 61 records, with reasons specified (see <a href="#CD013343-sec-0053">Excluded studies</a>). The remaining 36 records were eligible for inclusion. </p> </section> <section id="CD013343-sec-0043"> <h4 class="title">Included studies</h4> <p>The details of all included studies can be reviewed in the <a href="./references#CD013343-sec-0097" title="">Characteristics of included studies</a> table, with an overview of studies provided in <a href="#CD013343-tbl-0002">Table 1</a>. </p> <p>Thirty‐six studies met the inclusion criteria; 35 were double‐blind, randomised, placebo‐controlled trials of a parallel‐group design, including adults classified as having COPD or chronic bronchitis (or both). One trial was of a randomised crossover design; however, outcomes were measured following the initial treatment and follow‐up period, prior to crossover occurring, and, therefore, we included the initial study period in this review (<a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>). Two studies were multi‐arm, comparing two intervention groups and placebo (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>). In <a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>, the two intervention groups consisted of different doses of the same immunostimulant agent; in <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>, the two intervention groups consisted of the same immunostimulant agent and dose, but differed by the manufacturing country. Two studies separately examined several participant subsets versus placebo following initial randomisation, respectively creating four and six total comparison groups based on the nature or severity (or both) of the underlying airways disease (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a>). Two included studies present data in abstract form only; full reports were unable to be obtained (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>). </p> <p>The 36 RCTs recruited 6192 participants. Study duration ranged from three to 14 months, with a mean duration of 6.6 months.  </p> <p>Twelve studies examined the use of immunostimulants in participants with COPD only (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a>; <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>; <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). The remaining studies included participants with chronic bronchitis or COPD (or both), or chronic bronchitis alone. In studies where included participants were defined as having chronic bronchitis, it was assumed that some or all of the participants had COPD if it was documented in the inclusion criteria or text that they had a degree of airflow limitation or obstruction, or if mean baseline lung function values indicated this. </p> <p>Two studies indicated that the included participants concurrently had a degree of immunodeficiency (<a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>). <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a> described participants to have 'cell‐mediated immune deficiency' translated to be defined as "Multitest‐Merieux positive with no more than 2 antigens." <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>  indicated presence of 'borderline immunodeficiency' as an inclusion criterion, translated to be diagnosed by Merieux‐Multitest, chemotaxis, phagocytic activity of bronchoalveolar lavage macrophages, or sputum immunoglobulin A (IgA) concentration.  </p> <p>Where studies considered multiple participant groups based on the nature or severity (or both) of airways disease, we only extracted data for the relevant participant subsets. For example, <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a> presented data separately for participants with asthma, emphysema, and chronic bronchitis; we only extracted data for the emphysema and chronic bronchitis groups. In <a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>, where participants with chronic bronchitis were grouped into those with (Group II) or without (Group I) airflow limitation, we only extracted data for Group II participants as outcomes for this group were more completely reported by the study authors and deemed of greater relevance to this review.  </p> <section id="CD013343-sec-0044"> <h5 class="title">Inclusion and exclusion criteria</h5> <p>All studies involved adults who fulfilled criteria for chronic bronchitis, COPD, or both. Inclusion and exclusion criteria for each study were variable. Eight studies did not specify any exclusion criteria (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>; <a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a>), noting that <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a> and <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a> were available in abstract form only. Several did not clarify whether participants with other concomitant respiratory illnesses were excluded. Seven studies specified the inclusion criterion of participants experiencing an acute exacerbation at the time of study enrolment; however, all examined the preventive medium‐ to long‐term (rather than acute treatment) effects of the immunostimulant agent and hence were deemed to be acceptable to include in this review (<a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>; <a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a>).   </p> </section> <section id="CD013343-sec-0045"> <h5 class="title">Lung function</h5> <p>Seventeen studies reported baseline lung function values using FEV1 or FEV1 % predicted. Five of these indicated that the mean FEV1 % predicted of the included participants was less than 50% predicted; eight suggested that on average participants had moderate airflow limitation (mean FEV1 50% or greater and less than 80% predicted); one indicated participants on average had mild airflow limitation (mean FEV1 80% predicted or greater). Three studies reported absolute FEV1 volumes only. Of the remaining studies that did not specify baseline lung function, and excluding <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a> (abstract only), 10 included participants with either COPD alone or COPD or chronic bronchitis (or both). The remaining studies were those where included participants had chronic bronchitis, but it was not specified by study authors whether some or all participants may have had a degree of chronic, fixed airflow limitation. </p> </section> <section id="CD013343-sec-0046"> <h5 class="title">Age</h5> <p>The mean age of participants ranged from 35.2 years (<a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a>) to 82 years (<a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>). Three studies did not report age (<a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>; <a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>). Across the remainder of included studies, the mean age of participants was 60.0 years. Of these, 90% of studies included participant groups with a mean age between 45 and 70 years. </p> </section> <section id="CD013343-sec-0047"> <h5 class="title">Smoking status</h5> <p>Twenty studies reported baseline smoking status. Of the studies that analysed the number of participants who were either active or ex‐smokers, proportions ranged from 27.7% (<a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>) to 95.9% (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>). Several studies only reported the number of active smokers, and did not specifically indicate the presence or prevalence of ex‐smokers. </p> </section> <section id="CD013343-sec-0048"> <h5 class="title">Baseline exacerbation frequency</h5> <p>Twenty‐six studies reported the baseline mean exacerbation frequency, specified a history of frequent respiratory exacerbations as an inclusion criterion, or both.  </p> <p>Thirteen studies reported the baseline mean exacerbation frequency of study participants. Of these, 10 studies indicated participants had a mean exacerbation frequency of two or more in the preceding year (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>; <a href="./references#CD013343-bbs2-0031" title="RochemaureJ , LehertP , SauvagetJ , RobillardM , Betbeder-MatibetA . Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis. Revue de Pneumologie Clinique1988;44(1):43-7. RochemaureJ , LehertP , SauvagetJ , RobillardM , MurrayN , CastanierJC . Usefulness of immunomodulating agents. Lancet1987;2(8559):101. ">Rochemaure 1988</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>; <a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a>). Of the remaining three studies, one reported a mean exacerbation frequency over the preceding two years (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>), and two reported a mean exacerbation frequency but did not specify the timeframe over which this was measured (<a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>). However, <a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a> listed an exacerbation frequency of five or greater in the preceding year as an inclusion criterion for enrolment.  </p> <p>A further 13 studies specified a history of respiratory exacerbations as an inclusion criterion but did not report the baseline mean exacerbation frequency. Of these, nine studies stipulated that a history of two or more exacerbations in the preceding year was required for study inclusion (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0020" title="FoschinoBM , RestaO , CassanoA , AltieriA , GuidoP , PitiA , et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants. Minerva Pneumologica1995;34(2):39-44. ">Foschino 1995</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>; <a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). The other four studies listed an inclusion criterion of participants having a history of respiratory exacerbations, but did not specify an exacerbation rate threshold (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>; <a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a>; <a href="./references#CD013343-bbs2-0024" title="LiJ , ZhengJP , YuanJP , YangL , LuoDF , AnJY , et al. Protection of oral immunostimulant bronchovaxom against with chronic obstructive pulmonary disease. Respirology2005;10(3):A137. LiJ , ZhengJP , YuanJP , ZengGQ , ZhongNS , LinCY . Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal2004;117(6):828-34. ">Li 2004</a>).  </p> <p>Two studies reported variations on the metric of baseline mean exacerbation frequency in the 'baseline characteristics' table. <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a> reported the proportion of participants who had experienced three or fewer or more than three exacerbations over the year preceding the study. <a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a> reported the number of acute exacerbation events (rather than participants with events) over the four months preceding the study. </p> <p>There were no studies that indicated a significant difference in baseline exacerbation frequency between the included intervention and placebo groups.  </p> </section> <section id="CD013343-sec-0049"> <h5 class="title">Immunostimulants and dose</h5> <p>Summary tables regarding variations on the immunostimulant type, dose regimens, and total treatment durations are outlined in <a href="#CD013343-tbl-0002">Table 1</a> and <a href="#CD013343-tbl-0003">Table 2</a>. </p> <div class="table" id="CD013343-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Immunostimulants included in this review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trade name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Generic name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Active entity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pidotimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived (glycoproteins and membrane fractions of <i>Klebsiella pneumoniae</i>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Broncho‐Vaxom, Broncho‐Munal, Ommunal, Paxoral, Vaxoral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diribiotine CK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hymovis, Monovisc, Orthovisc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyaluronan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunoferon, Inmunol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycophosphopeptical (polysaccharide and protein compounds of <i>Candida utilis</i>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ismigen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyvalent mechanical bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lantigen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ribomunyl, Ribovac, Immucytal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived (proteoglycans of <i>Klebsiella pneumoniae</i> and ribosomal fragments from a range of bacterial pathogens) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymolin, Leucotrofina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymomodulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymic extract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symbioflor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived (components of <i>Enterococcus faecalis</i>) </p> </td> </tr> </tbody> </table> </div> <p>In 16 studies, the immunostimulant used was OM‐85, an oral bacterial lysate. Other immunostimulant agents studied included: AM3, an oral polysaccharide/protein compound isolated from <i>Candida utilis</i> (four studies); RU41740 (Biostim), an oral bacterially derived agent consisting of glycoproteins and membrane fractions of <i>Klebsiella pneumoniae</i> (three studies); Ismigen, a sublingual PMBL (two studies); Diribiotine CK, an oral/liquid bacterial lysate (two studies); thymomodulin, an oral thymic extract (two studies); pidotimod, an oral synthetic agent (two studies); D53 (Ribomunyl), a bacterially derived agent consisting of proteoglycans from <i>Klebsiella pneumoniae</i> and various ribosomal fractions, administered in aerosol and subcutaneous form (one study) and orally (one study); Lantigen B, a sublingual bacterial lysate (one study); Symbioflor, an oral/sublingual bacterial lysate (one study); and hyaluronan, a subcutaneous synthetic agent (one study).  </p> <p>Twenty‐six studies included intermittent dosing regimens across the total treatment duration period, and these appeared to be specific to the type of immunostimulant agent. Immunostimulants associated with continuous regimens were AM3 (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a>; <a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>), thymomodulin (<a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>; <a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>), pidotimod (<a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>), Symbioflor (<a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a>), and hyaluronan (<a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>). </p> <p>Across the sixteen studies that analysed OM‐85, there were no variations on the dose of 7 mg/day; however, there were differences in dose pattern and treatment duration, with five studies using a three‐month regimen (<a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0024" title="LiJ , ZhengJP , YuanJP , YangL , LuoDF , AnJY , et al. Protection of oral immunostimulant bronchovaxom against with chronic obstructive pulmonary disease. Respirology2005;10(3):A137. LiJ , ZhengJP , YuanJP , ZengGQ , ZhongNS , LinCY . Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal2004;117(6):828-34. ">Li 2004</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>; <a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a>), two studies using a four‐month regimen (<a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>), and nine studies using a five‐month regimen (<a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>; <a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). </p> <p>In the four studies that included AM3, two used a total daily dose of 3 g/day (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>), and two used a total daily dose of 1.5 g/day (<a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a>; <a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>). </p> <p>For the three studies that included RU41740 (Biostim), two used a dose of 2 mg/day for an initial interval followed by 1 mg/day for subsequent intervals (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a>). One was multi‐arm and used 2 mg/day for the first intervention group and 8 mg/day for the second intervention group (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>). </p> <p>For the two studies that included thymomodulin, one used a total daily dose of 120 mg/day (<a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>), and the other used a total daily dose of 240 mg/day (<a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>). </p> <p>For the two studies that included Ismigen, both used a total daily dose of 50 mg/day; however, one study used an intermittent dosing regimen over nine months' total duration (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>), and the other over three months' total duration (<a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>).  </p> <p>In the two studies that included Ribomunyl, the individual medication doses were not specified and there was variation between both the dose regimens and the method of administration, with <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a> using a combination of aerosol and subcutaneous routes and <a href="./references#CD013343-bbs2-0020" title="FoschinoBM , RestaO , CassanoA , AltieriA , GuidoP , PitiA , et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants. Minerva Pneumologica1995;34(2):39-44. ">Foschino 1995</a> using an oral form.  </p> </section> <section id="CD013343-sec-0050"> <h5 class="title">Study size and duration</h5> <p>Study size ranged from 19 participants (<a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>) to 494 participants (<a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>). Total study duration ranged from three months (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>; <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>) to 14 months (<a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a>) with a mean duration of 6.6 months. Total treatment duration, which included the time intervals between periods of treatment where intermittent dosing regimens were used, ranged from two months (<a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>) to nine months (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>) with a mean duration of four months. </p> </section> <section id="CD013343-sec-0051"> <h5 class="title">Countries</h5> <p>Ten studies were conducted in Italy; five in France; three in Switzerland; two in Spain; two in countries of the former Yugoslavia; two in China; and one each in Canada, Mexico, Egypt, Greece, Hungary and Germany. Six studies were conducted across two or more European/Scandinavian countries. </p> </section> <section id="CD013343-sec-0052"> <h5 class="title">Funding</h5> <p>Nine studies reported pharmaceutical sponsorship (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a>; <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a>; <a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a>; <a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>). Five studies did not specifically state pharmaceutical sponsorship; however, authorship details or the listed study address (or both) suggest pharmaceutical company associations (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>). <a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a> reported partial sponsorship from public grant funding. The remaining 21 studies did not specify any sponsorship or funding sources.  </p> </section> </section> <section id="CD013343-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded 92 studies after full‐text screening. See <a href="./references#CD013343-sec-0098" title="">Characteristics of excluded studies</a> table for reasons for exclusion.  </p> </section> </section> <section id="CD013343-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of our risk of bias judgements are presented in the risk of bias section of the <a href="./references#CD013343-sec-0097" title="">Characteristics of included studies</a> table, with an overview in <a href="#CD013343-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD013343-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD013343-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD013343-sec-0055"> <h4 class="title">Allocation</h4> <p>All included studies were reported to be randomised. However, for most studies the potential for allocation bias was unclear for both random sequence generation and allocation concealment, in that the authors did not state in sufficient detail the method of randomisation, where this took place, and how it was concealed. One study was at low risk of bias for both sequence generation and allocation concealment (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>). One study was at low risk for allocation concealment, but unclear for sequence generation (<a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>). One study was at high risk for both domains (<a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>). </p> <p>Of the studies that were unclear regarding potential for allocation bias, 21 did not provide any information regarding the randomisation process or how concealment was achieved. Five studies used random‐draw, randomly planned sequences, or randomisation codes, but gave no further details (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a>; <a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0031" title="RochemaureJ , LehertP , SauvagetJ , RobillardM , Betbeder-MatibetA . Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis. Revue de Pneumologie Clinique1988;44(1):43-7. RochemaureJ , LehertP , SauvagetJ , RobillardM , MurrayN , CastanierJC . Usefulness of immunomodulating agents. Lancet1987;2(8559):101. ">Rochemaure 1988</a>). Six studies used block permutation or stratified randomisation methods (or both), but it was unclear how the sequences were generated (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>). One study indicated randomisation by a computer‐generated sequence without further detail (<a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>). One study did not specify methods within the published report, but following further contact with the study author it was indicated computer‐generation may have been used (<a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a>). </p> <p>Two studies involved unbalanced randomisation in the intervention versus placebo group (<a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>: 2:1; <a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a>: 3:2). </p> <p>Most studies reported the baseline characteristics of treatment groups, which appeared well‐matched. The authors of several studies only reported characteristics for the overall study population (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>), or sparse numerical data regarding baseline characteristics (<a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>), but commented that the comparison groups were homogeneous for a range of metrics. One study provided data for its overall study population but did not specify whether the groups were well‐matched (<a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>). Two studies did not report on population baseline characteristics (<a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>), although <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a> was presented as an abstract only.  </p> </section> <section id="CD013343-sec-0056"> <h4 class="title">Blinding</h4> <p>All included studies were reported to be double‐blind. However, most did not provide sufficient information regarding the methods used to achieve blinding or the groups that were blinded; therefore, the potential of bias for these domains was unclear for 34 studies. One study was at low risk of bias for blinding of participants and personnel, but whether outcome assessors were blinded was not specified (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>). One study was at low risk of blinding of outcome assessors, but unclear for blinding of participants and personnel (<a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>).  </p> <p>Authors of eight studies indicated that the intervention and placebo formulations (tablets, capsules, or drops) were identical in appearance (<a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>; <a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). Whilst noted as an important feature of ensuring adequate participant and personnel blinding, if there was no elaboration on methodology to ensure blinding or the groups that were blinded (or both) were not specified, then this information alone was deemed insufficient to create confidence that there was adequate protection against performance and detection bias.  </p> </section> <section id="CD013343-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>Study dropout rate varied from a reported 0% (<a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>) to an estimated, but not explicitly stated, 72% (<a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>). When the proportion of dropouts was more than 20% of the total study population, we considered a 'high risk' rating; however, it was taken into account whether the dropouts were balanced in number and had occurred for similar reasons between study arms. The proportion of dropouts relative to study duration, and whether an ITT versus completer analysis had been performed, were also considerations.  </p> <p>Five studies were at high risk of attrition bias (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>), noting that <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a> was presented in abstract form only. In <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>, study authors reported their concerns about significant bias in this domain due to large amounts of missing data and flaws in analysis contributed to by invalid and inaccurate assessments of outcome events. As a result, the study authors and an independent group of experts deemed the study to be flawed and efficacy conclusions unable to be made based on the available study results. It may be relevant that this was a pharmaceutical company‐sponsored trial where the results for the primary outcome were unfavourable for the intervention group compared to placebo. Further information about the reported processes that led to this conclusion can be viewed in the <a href="./references#CD013343-sec-0097" title="">Characteristics of included studies</a> table. </p> <p>Seven studies were at low risk of attrition bias, as dropout rates were low or had been adequately described such that they were unlikely to have contributed to the quality and interpretation of study outcomes (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>; <a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a>).  </p> <p>The remaining studies were at unclear risk. An 'unclear' rating was given if dropout rates, reasons, distribution across the comparison groups, or a combination of these were not well‐described or if dropouts were unbalanced between groups. If dropout rates were high and per‐protocol analysis was undertaken, even if well‐balanced between groups and reasons provided, these studies were also deemed at unclear risk.  </p> <p>Six studies performed an ITT analysis (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a>), and one study analysed the full participant population due to a reported 100% completion rate (<a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>). Several studies did not describe the presence or absence of dropouts, but the number of participants analysed at study completion appeared to match those randomised at study commencement; therefore, it was not clear whether an ITT analysis was incorporated with dropouts or exclusions having occurred, or whether all participants had completed the study (<a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>; <a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a>; <a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a>; <a href="./references#CD013343-bbs2-0024" title="LiJ , ZhengJP , YuanJP , YangL , LuoDF , AnJY , et al. Protection of oral immunostimulant bronchovaxom against with chronic obstructive pulmonary disease. Respirology2005;10(3):A137. LiJ , ZhengJP , YuanJP , ZengGQ , ZhongNS , LinCY . Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal2004;117(6):828-34. ">Li 2004</a>; <a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>; <a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>). The remaining 22 studies used a per‐protocol analysis. Of these, one study indicated the allocation of an ITT sample based on its study flow diagram; however, they used a per‐protocol analysis for the primary study outcomes (<a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>).  </p> </section> <section id="CD013343-sec-0058"> <h4 class="title">Selective reporting</h4> <p>One study was at high risk for bias in this domain, due to methodological and outcome assessment flaws that were identified and reported by the study authors and an independent review panel (<a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; see <a href="./references#CD013343-sec-0097" title="">Characteristics of included studies</a> table). Excluding the two studies presented as abstract only (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>), nine studies were at unclear risk, because not all intended outcomes were reported, there was possible skew towards reporting of positive outcomes, or data had been presented in such a way that may have positively influenced the significance of the findings (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0020" title="FoschinoBM , RestaO , CassanoA , AltieriA , GuidoP , PitiA , et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants. Minerva Pneumologica1995;34(2):39-44. ">Foschino 1995</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>; <a href="./references#CD013343-bbs2-0031" title="RochemaureJ , LehertP , SauvagetJ , RobillardM , Betbeder-MatibetA . Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis. Revue de Pneumologie Clinique1988;44(1):43-7. RochemaureJ , LehertP , SauvagetJ , RobillardM , MurrayN , CastanierJC . Usefulness of immunomodulating agents. Lancet1987;2(8559):101. ">Rochemaure 1988</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). The remaining 24 studies appear to have reported sufficiently on all intended outcomes and were, therefore, judged at low risk of bias in this domain.  </p> </section> <section id="CD013343-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>One study indicated that baseline data for outcomes measuring the efficacy of the intervention was obtained through retrospective questionnaire, which may have introduced hindsight bias (<a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>). The impact of this on study outcomes was unclear, as baseline data did not appear to be relevant to primary or secondary outcome analysis. </p> </section> </section> <section id="CD013343-sec-0060"> <h3 class="title" id="CD013343-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD013343-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ immunostimulant vs. placebo for adults with chronic bronchitis or chronic obstructive pulmonary disease</a> </p> <p>See: <a href="./full#CD013343-tbl-0001">summary of findings Table 1</a> for an overview of the main results together with a summary of our confidence in the evidence per outcome. </p> <section id="CD013343-sec-0061"> <h4 class="title">Primary outcome: number of participants with no exacerbations during the study period</h4> <p>Sixteen studies reported this outcome directly or indirectly (by reporting the number of participants with an exacerbation as a number of proportion of the total group population, from which the number of participants with no exacerbations could be inferred). Fifteen were included in meta‐analysis; one study was not included, as outcomes were analysed over two discrete eight‐week time intervals and this duration was shorter than had been specified in our protocol criteria (<a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>).  </p> <p>Immunostimulant medication increased the overall odds of not experiencing an exacerbation over the study period compared to placebo (OR 1.48, 95% CI 1.15 to 1.90; I<sup>2</sup> = 53%; 15 studies, 2961 participants; <a href="./references#CD013343-fig-0008" title="">Analysis 1.1</a>; <a href="#CD013343-fig-0003">Figure 3</a>; moderate‐certainty evidence). For the mean comparator risk of 0.52, this corresponded to an NNTB of 11 (95% CI 7 to 29). For the extremes of low (0.05) comparator risks for this outcome, the NNTB was 46 (95% CI 25 to 143) and for high (0.68) comparator risks was 13 (95% CI 9 to 34).   </p> <div class="figure" id="CD013343-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD013343-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The heterogeneity across the 15 studies included in this analysis was moderate to high (I<sup>2</sup> = 53%), and was explored using preplanned subgroup analyses. Subgrouping for immunostimulant type was not associated with a consistent reduction of heterogeneity within subgroups, and the test for subgroup differences indicated that there was no evidence of a subgroup treatment effect (Chi<sup>2</sup> = 2.82, degrees of freedom (df) = 3 (P = 0.42), I<sup>2</sup> = 0%; <a href="./references#CD013343-fig-0009" title="">Analysis 1.2</a>). Preplanned subgroup analyses were also undertaken to assess for any variations in treatment effect related to baseline lung function and exacerbation frequency. Results of the subgroup and sensitivity analyses performed are elaborated on in 'Subgroup and sensitivity analyses' below.  </p> <p>The funnel plot indicated the absence of small, neutral, or negative studies, and the likely presence of publication bias which may have skewed the pooled effect estimate towards a more positive result (<a href="#CD013343-fig-0004">Figure 4</a>). However, exclusion of the five small, positive studies by sensitivity analysis did not significantly lessen the effect estimate.  </p> <div class="figure" id="CD013343-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD013343-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Two included studies measured this outcome in discrete time intervals (<a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>). Unlike <a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a> however, the data sets from the initial time period were incorporated into meta‐analysis as they had been measured over longer intervals of three months (<a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>) and six months (<a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a>). The later data sets were not included in meta‐analysis. The data set for the first, rather than the last, measurement period from baseline was preferentially incorporated, as it was considered that the study participants were more likely to be truly randomised at study commencement and there would be less risk of a carry‐over effect from earlier treatment exposure, which may potentially confound outcome data.  </p> <p><a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a> (pidotimod) measured outcomes over four months in discrete two‐month intervals. Authors reported that fewer participants experienced exacerbations in the intervention group compared to placebo for both the zero‐ to two‐month interval (9/88 participants with intervention versus 57/75 participants with placebo) and the three‐ to four‐month interval (0/25 participants with intervention versus 13/26 participants with placebo) (reported P &lt; 0.001 for both time intervals). However, concerns around methodology including significantly high and unexplained dropout rates led to a 'high risk' judgement for attrition bias, and the calculated ORs and CIs for the inverse of these results (i.e. the number of participants with <i>no</i> exacerbations) also suggested data imprecision for both the zero‐ to two‐month (OR 27.80, 95% CI 11.65 to 66.32; 163 participants) and three‐ to four‐month (OR 51.0, 95% CI 2.81 to 925.71; 51 participants) study intervals.  </p> <p><a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a> (Diribiotine CK), measured number of participants with no exacerbations over six months in two discrete three‐month intervals. The zero‐ to three‐month data set was included in meta‐analyses. Due to concerns regarding attrition bias, this study was at 'high risk' for this domain; however, exclusion by sensitivity analysis did not lead to augmentation of the pooled effect estimate. The four‐ to six‐month data set was not included, but for this later time period the study authors reported a difference in the number of participants without an exacerbation in the intervention group compared to placebo (5/10 participants with intervention versus 2/10 participants with placebo; OR 3.5, 95% CI 0.47 to 25.90; P = 0.22). Data imprecision lowers the certainty in this effect estimate.  </p> <p><a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a> (Symbioflor) measured number of participants with no exacerbations over 14 months in discrete six‐ and eight‐month intervals. The zero‐ to six‐month data set was included in meta‐analysis. Results for the seven‐ to 14‐month, post‐treatment follow‐up period indicated that the number of participants with an exacerbation during this time was less in the intervention group compared to placebo (P = 0.013, as reported by the study authors). The associated point estimate of effect suggested an increased odds of experiencing no exacerbations with intervention compared to placebo (OR 1.83, 95% CI 0.9 to 3.7; 136 participants); however, the estimate is imprecise.  </p> <p>Sixteen other studies that did not report the number of participants with or without an exacerbation, instead reported on alternative exacerbation metrics such as the number of exacerbation events or the mean exacerbation rate for the study period. The studies varied in the way they presented count data in terms of method of presentation, reporting of variance, and rate time frames. Therefore, this information was not extracted or pooled for the purposes of this systematic review. </p> </section> <section id="CD013343-sec-0062"> <h4 class="title">Primary outcome: mortality (all‐cause)</h4> <p>Seven studies (2003 participants) reported mortality data (<a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a>; <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>). Five were combined in meta‐analysis. We did not include <a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a> as they reported a 1.2% overall mortality rate (172 participants), but it was not specified which comparison groups the deaths were associated with, and <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a> reported zero‐event rates in both arms (273 participants). </p> <p>Immunostimulants probably result in little to no difference in all‐cause mortality compared to placebo, measured over a mean follow‐up period of eight months (OR 0.64, 95% CI 0.37 to 1.10; I<sup>2</sup> = 0%; 5 studies, 1558 participants; <a href="./references#CD013343-fig-0015" title="">Analysis 1.8</a>; <a href="#CD013343-fig-0005">Figure 5</a>; moderate‐certainty evidence); however, CIs were wide and included the potential for both a clinically important difference and no difference.  </p> <div class="figure" id="CD013343-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD013343-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The studies that were meta‐analysed only included two immunostimulant agents; OM‐85 (three studies) and Ismigen (two studies).  </p> <p><a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a> contributed most of the weight in the meta‐analysis for all‐cause mortality and recruited elderly participants from residential care facilities (mean age 82 years) with a diagnosis of chronic bronchitis. Reported baseline characteristics data suggested high rates of comorbidity in both groups. Therefore, the results from this study may be less applicable to the general chronic bronchitis or COPD (or both) population; however, there was little impact on the pooled effect estimate when this study was excluded in sensitivity analysis.  </p> </section> <section id="CD013343-sec-0063"> <h4 class="title">Secondary outcome: mortality (respiratory‐related)</h4> <p>Two larger studies that had reported on all‐cause mortality also reported respiratory‐related mortality (<a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>). Both analysed the immunostimulant OM‐85 over six months. Results from pooled analysis indicated there may be little to no difference in respiratory‐related mortality (OR 0.40, 95% CI 0.15 to 1.07; I<sup>2</sup> = 0%; 2 studies, 735 participants; <a href="./references#CD013343-fig-0021" title="">Analysis 1.14</a>; low‐certainty evidence). However, data availability, imprecision, and indirectness lower the certainty in this effect estimate. The concerns regarding the applicability and generalisability of the data presented in <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>, with its inclusion of an elderly, comorbid study population, carried greater weight for this outcome considering this meta‐analysis included only two studies.  </p> </section> <section id="CD013343-sec-0064"> <h4 class="title">Secondary outcome: quality of life</h4> <p>Although several studies reported subjective participant or physician (or both) estimations of well‐being, only six explored the impact of immunostimulants on health‐related quality of life (HRQoL) compared to placebo using validated assessment tools. The tools used included the SGRQ (<a href="./references#CD013343-bbs2-0137" title="JonesPW , QuirkFH , BaveystockCM , LittlejohnsP . A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. American Review of Respiratory Disease1992;145(6):1321-7.">Jones 1992</a>), the 36‐item Short Form Health Survey (SF‐36), the 12‐item Short Form Health Survey (SF‐12), and the Chronic Cough Impact Questionnaire (CCIQ) (<a href="./references#CD013343-bbs2-0105" title="BaiardiniI , BraidoF , FassioO , TarantiniF , PasqualiM , TarchinoF , et al. A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire. Allergy2005;60:482-8.">Baiardini 2005</a>).  </p> <p>In three studies, investigators assessed the impact of the intervention on quality of life using the SGRQ (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>). <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> used the SF‐36. <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a> used both the SF‐12 and CCIQ. <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a> used an unnamed, 9‐point 'Index of improvement for quality of life' scale that referenced an earlier study in which the scale appeared to have been validated (<a href="./references#CD013343-bbs2-0130" title="GrossiE , BlasiF , NastriA , MontanariC . Predittivita di una scala di valutazione sintomatologica nella diagnosi delle nacutizzazioni in corso di BPCO: validazione mediante modello di analisi discriminante multivariata. Rassegna di Patologia Dell'Apparato Respiratorio1989;IV(3):1-103.">Grossi 1989</a>); the original publication of this article could not be obtained. </p> <p>The SGRQ is made up of three subscales – symptoms, activities, and impacts – to yield a total score ranging from 0 to 100 (<a href="./references#CD013343-bbs2-0137" title="JonesPW , QuirkFH , BaveystockCM , LittlejohnsP . A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. American Review of Respiratory Disease1992;145(6):1321-7.">Jones 1992</a>). A lower score indicates a better quality of life. Total SGRQ scores from two studies, both of which assessed the immunostimulant AM3, were combined in meta‐analysis (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>); scores from <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a> could not be incorporated as there were no numerical data presented, with authors reporting that there were no differences between study arms. </p> <p>There was a reduction in total SGRQ scores for participants receiving immunostimulant compared to placebo (MD −4.59, 95% CI −7.59 to −1.59; I<sup>2</sup> = 0%; 2 studies, 617 participants; <a href="./references#CD013343-fig-0022" title="">Analysis 1.15</a>; very low‐certainty evidence). This effect met the minimum clinically important difference (MCID) of a reduction of 4 units on the SGRQ scale (<a href="./references#CD013343-bbs2-0138" title="JonesPW . St. George's Respiratory Questionnaire: MCID. COPD2005;2(1):75-9.">Jones 2005</a>). However, the upper limit of the CI for this effect did not clear the MCID and the possibility of a non‐meaningful difference could not be excluded. Several other factors contributed to a lowering of the certainty of this effect estimate; <a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a> was presented as an abstract only, had a short duration of follow‐up (three months), and, due to inconsistencies in the reported number of participants for each arm, was at high risk for attrition bias. Additionally, there were no standard deviations for the total scores in each study arm reported and, for the purposes of meta‐analysis these were instead calculated from the reported P value for the MD between comparison groups. </p> <p><a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a> reported both mean total SGRQ scores and mean change‐from‐baseline scores over the six‐month study period for 253 participants. There was a difference in the total SGRQ scores (MD −4.6) and total 'activity' subcomponent scores (MD −7.1) described between the comparison groups at six months, favouring the intervention (P &lt; 0.05 for both outcomes, as reported by study authors). The differences between study arms with respect to the total 'symptom' (MD −3.4) and 'impact' (MD −4.1) subcomponent scores, although favouring intervention, were reportedly non‐significant. In assessing change in mean scores from baseline, there were no differences for total SGRQ (MD −3.3; reported P = 0.076), 'activity' (MD −1.7), and 'impact' (MD −3.1) subcomponent scores, comparing intervention to placebo. However, there was a meaningful difference favouring intervention between study arms in the change of mean 'symptom' subcomponent scores from baseline (MD −5.7; reported P &lt; 0.05).  </p> <p>For the three studies that analysed the effect of an immunostimulant agent on quality of life using alternative assessment tools, there were no numerical data were presented by trialists to enable qualitative or quantitative analysis in this review (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>). In <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a> (Ismigen; 12 months' follow‐up; 288 participants) and <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> (OM‐85; six months' follow‐up; 381 participants), the study authors reported no differences in the quality‐of‐life scale scores between intervention and placebo groups, with data not shown. In <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a> (thymomodulin; three months' follow‐up; 236 participants) authors provided a graphical representation of nine quality‐of‐life domains and presented data per domain for both intervention and placebo groups as a ratio of percentage of improved participants to percentage of participants who were 'worse' at the completion of the study per domain. They reported improvement in all nine domains for the intervention group and in four domains for the placebo group (reported P &lt; 0.05). There was no comparison between the intervention and placebo groups for each domain or overall reported. </p> </section> <section id="CD013343-sec-0065"> <h4 class="title">Secondary outcome: number of participants requiring antibiotics </h4> <p>Seven studies reported number of participants requiring antibiotics; five were combined in meta‐analysis (<a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>; <a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a>; <a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>). Two studies could not be included as outcomes were analysed in discrete monthly time intervals, and this duration was shorter than our specified protocol criteria (<a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). The studies combined in meta‐analysis included the immunostimulant agents RU41740 (Biostim) (one study), OM‐85 (one study), Lantigen B (one study), Symbioflor (one study), and Diribiotine CK (one study). The two studies not meta‐analysed both examined the effects of the immunostimulant OM‐85 BV.  </p> <p>Immunostimulants likely reduced the overall odds of receiving antibiotic treatment for an exacerbation over the study period compared to placebo (OR 0.34, 95% CI 0.18 to 0.63; I<sup>2</sup> = 38%; 5 studies, 542 participants; <a href="./references#CD013343-fig-0023" title="">Analysis 1.16</a>; <a href="#CD013343-fig-0006">Figure 6</a>; moderate‐certainty evidence). Although the upper limit for the risk ratio CI crossed the 25% relative risk threshold for appreciable benefit (RR 0.64, 95% CI 0.5 to 0.82), the optimal information size criteria was met and the CI did not include the null effect.  </p> <div class="figure" id="CD013343-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD013343-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>The heterogeneity of these five studies was low to moderate, and likely due to the clinical and methodological diversity between studies, noting that each included study examined a different immunostimulant agent. However, the direction of effect was consistent across studies. One studies included in the analysis was at high risk for attrition bias (<a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>). Another study included participants with COPD and concurrent 'borderline immune deficiency' and there were concerns about the applicability of these data as a result (<a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>). Another examined an elderly population (mean age 81.8 years), which may affect applicability and generalisability of these data to a general chronic bronchitis/COPD population (<a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>). However, individual exclusion of these studies by sensitivity analyses had little impact on the pooled effect estimate.  </p> <p>One study included in the meta‐analysis measured number of participants requiring antibiotics over six months in two discrete three‐month intervals (<a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a>). We incorporated only the initial zero‐ to three‐month data set. The study authors also presented data on the number of participants not requiring antibiotics over the four‐ to six‐month period. The inverse of the reported results for this interval (i.e. the number of participants <i>requiring</i> antibiotics) corresponded to an OR of 0.64 (95% CI 0.11 to 3.92; P = 0.65; 20 participants); however, this estimate is imprecise.  </p> <p>Two studies analysed the effect of immunostimulant on the number of participants requiring antibiotics compared to placebo over six months in discrete monthly intervals (<a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). <a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a> (104 participants) presented data in graphical form, and authors only reported on the reduction in the proportion of participants requiring antibiotics compared to study entry in the intervention group (reported P &lt; 0.05). There were no statistical comparisons of the intervention and placebo groups presented for this outcome at any of the study time points. <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a> (62 participants) reported that for the first three months of the trial there were no differences in the number of participants requiring antibiotics between the study arms, with numerical data not shown. They reported data for the four‐ and six‐month time intervals, with differences noted in the proportion of participants requiring antibiotics in the immunostimulant group compared to placebo (four months: P &lt; 0.001; six months: P &lt; 0.002; reported by the authors). For both studies, it was difficult to draw conclusions about the impact of immunostimulants on the requirement for antibiotic use, as the short time intervals over which this outcome was measured were considered likely to overestimate treatment effect. Additionally, the high risk of attrition bias in <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a> impacted interpretation of data quality and certainty regarding the effect estimates. </p> <p>Several studies that did not report this outcome presented data regarding antibiotic use by alternative metrics; for example, as duration of antibiotic therapy (eight studies) or the incidence of antibiotic use (three studies).  </p> </section> <section id="CD013343-sec-0066"> <h4 class="title">Secondary outcome: exacerbation duration</h4> <p>Twenty‐one studies analysed exacerbation duration. Seventeen studies were initially included in meta‐analysis; three studies reported results over discrete intervals that did not meet our protocol criteria for minimum duration of outcome measurement (<a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>). One study reported that there were no differences in this outcome between comparison groups, with no numerical data shown (<a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>). </p> <p>Of the studies included in the meta‐analysis, one measured outcomes over 12 months in discrete three‐month intervals (<a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>); we incorporated only the first zero‐ to three‐month period from baseline.  </p> <p>The meta‐analysis performed for these 17 studies (1693 participants) indicated a pooled effect estimate that favoured intervention, measured over a mean duration of 6.4 months; however, this result was associated with an unacceptably high level of heterogeneity (I<sup>2</sup> = 92%; <a href="./references#CD013343-fig-0024" title="">Analysis 1.17</a>). Therefore, the mean effect was difficult to interpret and draw conclusions from, and the likelihood of data skew was also considered to make parametric analysis less robust. Consensus decision was made to disable the forest plot totals, although the graph has still been included in this review for transparency and reference purposes.  </p> <p>The degree of heterogeneity seen was interpreted to be due to methodological and clinical diversity related to study interventions, design, population (noting variability in smoking prevalence and mean participant age between included studies), potentially variable outcome definitions and measures of effect, and the use of a continuous variable. The variability in absolute values occurring between studies may indicate that results could have been presented by authors as either the mean duration of an exacerbation episode, or as the total or cumulative number of exacerbation days averaged over the number of participants for the study duration. For several studies, this differentiation was unclear. In five studies measures of variance had not been reported by the trialists; these were instead calculated and assumed from the reported MDs and P values (<a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0020" title="FoschinoBM , RestaO , CassanoA , AltieriA , GuidoP , PitiA , et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants. Minerva Pneumologica1995;34(2):39-44. ">Foschino 1995</a>; <a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>; <a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a>). A sensitivity analysis, excluding these studies and separately those that that were at high risk of bias for any domain, did not significantly modify the pooled effect estimate.  </p> <p>In lieu of formally meta‐analysing this outcome, we performed a post hoc synthesis of data by vote‐counting based on direction of effect, whereby the effect estimate for each study was categorised as a binary metric (beneficial versus harmful) and a binomial probability test applied to determine the probability of observing the result if the intervention was truly ineffective (<a href="#CD013343-fig-0007">Figure 7</a>). Of the 18 available studies, one provided no information about direction of effect and was excluded (<a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>). By this method, there was evidence that immunostimulant agents had an effect on reducing exacerbation duration, with 16/17 included studies favouring the intervention (94%, 95% CI 73% to 99%; P = 0.0002). Sensitivity analyses that excluded studies at high risk of bias in any domain or for which missing variance data had been imputed did not impact significantly on these results.  </p> <div class="figure" id="CD013343-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Effect direction plot and sign test for the outcome of exacerbation duration." data-id="CD013343-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-07.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Effect direction plot and sign test for the outcome of exacerbation duration.</p> </div> </div> </div> <p><a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a> (thymomodulin; 88 participants) measured the impact of exacerbation duration over 12 months in discrete three‐month intervals. We included the zero‐ to three‐month data set in the above analyses, but not the later time periods. Authors reported reductions in exacerbation duration in the intervention group compared to placebo during the four‐ to six‐month (MD −2.09; reported P = 0.04), seven‐ to nine‐month (MD −1.26; reported P = 0.15) and 10‐ to 12‐month (MD −0.49; reported P = 0.44) intervals.  </p> <p><a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a> (AM3; 40 participants) analysed exacerbation duration over four months in discrete two‐month intervals. They reported a longer exacerbation duration in the intervention group versus placebo in the zero‐ to two‐month period (MD 1.65), and conversely a reduction in duration favouring immunostimulant over the three‐ to four‐month period (MD −2.45; reported P &lt; 0.005).  </p> <p><a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a> (pidotimod) measured exacerbation duration over five months in two‐ and three‐month discrete intervals. Authors presented data for all participants (492 participants at two months; 481 at five months), and also for those with a history of three or fewer exacerbations in the preceding year (242 participants two months; 240 at five months). For all participants, there was a reduced exacerbation duration in the intervention group compared to placebo for both time periods, but authors reported this difference was only significant in the second, three‐month period (MD −2.2; reported P &lt; 0.01). For those who were less‐frequent exacerbators, there was a difference favouring intervention across both time periods (MD −1.6 for zero to two months; and MD −2.2 for three to five months; reported P &lt; 0.05 for both intervals). There were no data for those who were more‐frequent exacerbators (greater than three exacerbations in the preceding year). </p> <p><a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a> (OM‐85; 62 participants) analysed the impact of immunostimulant on exacerbation duration over six months, in one‐month intervals. They reported numerical data for all time periods. In the first and third months, exacerbation duration was less in the intervention groups compared to placebo, but this difference was reported to be non‐significant. In the second month, the mean exacerbation duration was higher in the intervention group (MD +0.79). For the remainder of the study, authors reported a reduction in the mean exacerbation duration in the intervention group compared to placebo when measured over the fourth (MD −1.14; reported P &lt; 0.001), fifth (MD −0.52; reported P &lt; 0.05), and sixth months (MD −0.16; P &lt; 0.002). </p> </section> <section id="CD013343-sec-0067"> <h4 class="title">Secondary outcome: hospitalisation duration (respiratory‐related)</h4> <p>Seven studies analysed the effect of immunostimulant on hospitalisations (either all‐cause or respiratory‐related) compared to placebo (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>; <a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a>). Three of these reported mean respiratory‐related hospitalisation duration; however, data were unable to be meaningfully combined in meta‐analysis (<a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a>). A forest plot was initially created combining the data on 559 participants from <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a> and <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> (<a href="./references#CD013343-fig-0025" title="">Analysis 1.18</a>), but heterogeneity was high (I<sup>2</sup> = 83%) and the pooled effect estimate difficult to interpret, therefore, totals were disabled. <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a> could not be included as the trialists did not report measures of variance, and these were not estimable using alternative statistical methods from the data provided. </p> <p><a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> (OM‐85; 381 participants) reported that the mean duration of respiratory‐related hospitalisation was shorter in the immunostimulant group (6.4 days) than in the placebo group (11.3 days) over six‐month follow‐up, although this difference was not significant (MD −4.9, 95% CI −7.47 to −2.33; reported P = 0.058). <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a> (Ismigen; 178 participants) reported a reduced mean respiratory‐related hospitalisation duration in the immunostimulant group compared to placebo over 12‐month follow‐up (MD −1.6, 95% CI −2.5 to −0.7; reported P &lt; 0.05). <a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a> (OM‐85; 19 participants) reported a mean hospitalisation duration of 0.8 days in the intervention group over four months versus 1 day in the placebo group, but did not report measures of variance or statistical significance.  </p> <p>Seven studies measured the impact of immunostimulant therapy on hospitalisations using a range of other metrics. These included the number of respiratory‐related hospitalisation events (three studies), number of all‐cause hospitalisation events (two studies), number of participants requiring hospitalisation for a respiratory cause (one study), number of participants requiring hospitalisation for any cause (one study), total respiratory‐related hospitalisation days (three studies), total all‐cause hospitalisation days (two studies), and mean number of hospitalisation events per participant (one study). The three studies (847 participants) that reviewed total respiratory‐related hospitalisation days were larger trials conducted over a mean follow‐up of 10 months and examined the immunostimulants OM‐85 and Ismigen. All reported decreases in total hospitalisation time in the intervention groups compared to placebo (percentage difference: <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>: Ismigen, −60%; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>: Ismigen, −53%; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>: OM‐85, −55%). </p> </section> <section id="CD013343-sec-0068"> <h4 class="title">Secondary outcome: adverse events/side effects</h4> <p>Twenty‐seven studies reported the proportion of participants who experienced an adverse event over the study period. Seven, involving a total of 955 participants, reported no events in either study arm (<a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a>; <a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a>; <a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a>; <a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a>; <a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a>; <a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a>; <a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a>). The remaining 20 studies were included in meta‐analysis. </p> <p>There was no evidence of a difference in the odds of experiencing an adverse event when receiving immunostimulant compared to placebo (OR 1.01, 95% CI 0.84 to 1.21; I<sup>2</sup> = 0%; 20 studies, 3780 participants; <a href="./references#CD013343-fig-0026" title="">Analysis 1.19</a>; high‐certainty evidence). The CIs included the null effect, but optimal information size criteria were met and the risk ratio upper limit did not cross the relative risk threshold for appreciable harm (RR 1.02, 95% CI 0.92 to 1.13).  </p> <p>Of the remaining studies, <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> reported the number of adverse event occurrences between comparison groups (138 events in 191 participants with intervention versus 151 events in 190 participants with placebo). <a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a> reported treatment intolerance in 2% of 184 participants overall but did not specify which groups the affected participants belonged to. <a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a> reported 51 cases of 'mild' adverse reaction events in 172 participants overall and did not specify in which groups these events occurred, although authors stated that there were no significant differences between the study arms. Six studies did not report adverse events (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>; <a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a>; <a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a>; <a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a>; <a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a>; <a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a>).  </p> <p>The nature of reported adverse events varied between studies, but in both intervention and placebo groups more frequently included gastrointestinal upset (nausea, dyspepsia, diarrhoea, constipation, abdominal pain), skin itch or rash, upper or lower respiratory tract symptoms, and fever. Eight studies reported study withdrawals that were related to the development of adverse events/side effects; however, these were balanced across the comparison groups (<a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a>; <a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a>; <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a>; <a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a>; <a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a>; <a href="./references#CD013343-bbs2-0031" title="RochemaureJ , LehertP , SauvagetJ , RobillardM , Betbeder-MatibetA . Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis. Revue de Pneumologie Clinique1988;44(1):43-7. RochemaureJ , LehertP , SauvagetJ , RobillardM , MurrayN , CastanierJC . Usefulness of immunomodulating agents. Lancet1987;2(8559):101. ">Rochemaure 1988</a>; <a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a>). In the remaining studies, there were either no dropouts that occurred due to adverse events or the trialists did not report this.   </p> </section> <section id="CD013343-sec-0069"> <h4 class="title">Subgroup and sensitivity analyses</h4> <section id="CD013343-sec-0070"> <h5 class="title">Subgroup analyses</h5> <p>Planned subgroup analyses were undertaken for the primary outcomes only; that is, participants with no exacerbations and mortality (all‐cause), to investigate for any potential heterogeneity encountered and differences in treatment effect. Subgrouping was performed by immunostimulant type, severity of COPD based on lung function testing (FEV1 50% or greater versus less than 50%), mean baseline exacerbation frequency (two or more in the preceding year versus fewer than two in the prespecified year or unspecified), treatment duration (three months or less versus greater than three months), and study duration (three to less than six months versus six months to less than 12 months versus 12 months or greater). </p> <p>For the number of participants with no exacerbations, the heterogeneity of the 15 studies included in meta‐analysis was moderate (I<sup>2</sup> = 53%). Heterogeneity did not consistently appear to be lower within any of the subgroups than across all studies (<a href="./references#CD013343-fig-0009" title="">Analysis 1.2</a>; <a href="./references#CD013343-fig-0010" title="">Analysis 1.3</a>; <a href="./references#CD013343-fig-0011" title="">Analysis 1.4</a>; <a href="./references#CD013343-fig-0012" title="">Analysis 1.5</a>; <a href="./references#CD013343-fig-0013" title="">Analysis 1.6</a>); where subgroups had no or low levels of heterogeneity suggested by the I<sup>2</sup> statistic, the associated P value for the Chi<sup>2</sup> test was &gt; 0.1.  </p> <p>To further explore possible sources of heterogeneity associated with this outcome, we performed a post hoc subgroup analysis differentiating studies by the decade of publication (<a href="./references#CD013343-fig-0014" title="">Analysis 1.7</a>). Moderate‐to‐high levels of heterogeneity remained within the subgroups, particularly across the studies published between 1990 and 1999 (I<sup>2</sup> = 70%) and 2000 to 2009 (I<sup>2</sup> = 66%). </p> <p>In terms of the potential impact of subgrouping on estimates of treatment effect, there were no significant subgroup effects found and the test for subgroup differences across all subgroup analyses was negative, for both primary outcomes. However, for the outcome of participants with no exacerbations, as there was moderate to substantial unexplained heterogeneity demonstrated between trials within most subgroups, the validity of the treatment effect estimate for each subgroup and the true presence or absence of subgroup differences was uncertain. Additionally, in the subgroup analyses of immunostimulant type (<a href="./references#CD013343-fig-0009" title="">Analysis 1.2</a>), lung function (<a href="./references#CD013343-fig-0010" title="">Analysis 1.3</a>), study duration (<a href="./references#CD013343-fig-0013" title="">Analysis 1.6</a>), and decade of publication (<a href="./references#CD013343-fig-0014" title="">Analysis 1.7</a>), several subgroups contained a limited number of studies; therefore, uneven covariate distribution also limits certainty of the impact of subgrouping effect. For all‐cause mortality, this is also a concern, with low minimum (two) and maximum (three) subgroup study numbers.  </p> <p>When the number of participants with no exacerbations was subgrouped by decade of publication, visualisation of the forest plot implied a trend towards the production of more conservative results in studies that were more recently published. Studies published between 2010 and 2019 (OR 1.08, 95% CI 0.79 to 1.48; I<sup>2</sup> = 0%; 2 studies, 672 participants) or between 2000 and 2009 (OR 1.27, 95% CI 0.98 to 1.66; I<sup>2</sup> = 66%; 4 studies, 1002 participants) appeared to have a lesser effect size than those published between 1990 and 1999 (OR 1.45, 95% CI 1.12 to 1.88; I<sup>2</sup> = 70%; 4 studies, 965 participants) and before 1990 (OR 2.15, 95% CI 1.26 to 3.66; participants 322; studies 5; I<sup>2</sup> = 25%; 5 studies, 322 participants). However, inferences about effect sizes were limited by the degree of heterogeneity within the subgroups and uneven covariate distribution.  </p> </section> <section id="CD013343-sec-0071"> <h5 class="title">Sensitivity analyses</h5> <p>In accordance with our protocol, sensitivity analyses were performed excluding studies at high risk of bias in any of the six domains, for any outcome. Where sensitivity analyses were undertaken, this is specified above under the relevant outcome headings. This type of sensitivity analysis did not lead to appreciable modification of the pooled effect estimate for any of the review outcomes.  </p> <p>Post hoc sensitivity analyses were also performed excluding trials that were more likely to lessen the overall data quality, to determine the impact of their absence on the effect estimate. These analyses are also specified above under the relevant outcome headings. Where these were conducted, this was little to no impact on the effect estimates observed. </p> <p>Last, planned sensitivity analyses were undertaken for outcomes where there had been assumptions concerning missing data. This was largely relevant for the HRQoL and exacerbation duration outcomes, where missing variance measures for individual studies had been calculated from reported MDs and P values. As the meta‐analysis for HRQoL only contained two studies, conclusions were unable to be drawn from a sensitivity analysis that excluded the study where data assumptions had been made (<a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a>). The meta‐analysis for exacerbation duration was not undertaken for aforementioned reasons; instead, this outcome was analysed dichotomously using a direction‐of‐effect table (<a href="#CD013343-fig-0007">Figure 7</a>). Sensitivity analyses were performed excluding the studies at high risk of bias in any domain or those where data had been assumed, both of which had little impact on the overall proportion of 'positive' studies or associated binomial probability.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013343-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013343-sec-0072"></div> <section id="CD013343-sec-0073"> <h3 class="title" id="CD013343-sec-0073">Summary of main results</h3> <p>The review included 36 studies involving 6192 participants. Studies were published between 1981 and 2015. Study duration ranged from three to 14 months. Immunostimulants investigated were OM‐85, AM3,<i> </i>RU41740 (Biostim), Ismigen, Diribiotine CK, thymomodulin, pidotimod, D53 (Ribomunyl), Lantigen B, Symbioflor, and hyaluronan, with administration including oral, sublingual, and subcutaneous routes. Twenty‐six studies included intermittent, rather than continuous, dosing regimens. The risks of bias of the included studies were mostly low or unclear.  </p> <p>The mean age of study participants ranged between 35.2 and 82 years. Twelve studies examined participants with COPD only. Seventeen studies reported baseline lung function values; most indicated a moderate‐to‐severe degree of airflow limitation. Nineteen studies indicated inclusion of participants with a mean baseline exacerbation frequency of two or more in the preceding year. </p> <section id="CD013343-sec-0074"> <h4 class="title">Primary outcomes</h4> <p>Participants administered an immunostimulant agent for a mean duration of six months were slightly more likely to be free of exacerbations during that time (OR 1.48, 95% CI 1.15 to 1.90; 15 studies, 2961 participants; moderate‐certainty evidence), although this result was moderately heterogeneous (I<sup>2</sup> = 53%). Based on a mean estimate of baseline risk of 52%, 11 (95% CI 7 to 29) participants required treatment for this duration for one to be exacerbation‐free.  </p> <p>Five studies were included in meta‐analysis for all‐cause mortality, with the pooled result suggesting that immunostimulants probably result in little to no difference in all‐cause mortality measured over a mean duration of eight months, although the CIs were not sufficiently narrow to exclude a clinically important difference (OR 0.64, 95% CI 0.37 to 1.10; 5 studies, 1558 participants; moderate‐certainty evidence).  </p> <p>Immunostimulants increased the odds of participants being exacerbation‐free in all but three studies (<a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a>; <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>; <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>). <a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a> examined the effect of the Ismigen compared to placebo over 12 months in 288 participants. The study was well‐described and at low risk of bias for half of the domains, with no high‐risk judgement in any domain. Study authors found no difference between the proportion of participants with no exacerbations in the intervention (70.55%) and placebo (71.13%) groups, postulating that the reasons for this may have been due to the low general exacerbation rate seen among study participants (greater than 70% participants did not experience an exacerbation over the study duration), and 27% dropout rate across the study (well‐described, ITT analysis used). Similarly <a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a>, which examined the effect of OM‐85 over six months in 381 participants, was at low risk of bias for half of the domains, with no high‐risk judgement in any domain. Authors reported no difference between intervention and placebo with respect to the number of participants experiencing one or more exacerbations during the study period (P = 0.872, as reported in the text of the paper). Reported proportions equated to 55.5% of participants in the immunostimulant group and 56.3% of participants in the placebo group with no exacerbations during the study period. It was suggested by the authors that this observed result may have been related to more frequent recording of respiratory events that did not meet the criteria definition for an exacerbation in the placebo compared to the immunostimulant group. In <a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a>, where trialists analysed the effect of OM‐85 versus placebo in 357 participants over six months, the negative direction of the point estimate of effect for the immunostimulant group was more noticeable (OR 0.81, 95% CI 0.52 to 1.24), although CIs were wide and included the possibility of no difference or a positive effect. Of note, this study was at high risk for attrition bias and selective outcome reporting; the study authors, as well as an independent group of experts, considered the study to be flawed due to the degree of ineligible and missing data, and considered  that conclusions could not be drawn from this result. All three studies were associated with pharmaceutical company sponsorship. </p> </section> <section id="CD013343-sec-0075"> <h4 class="title">Secondary outcomes</h4> <p>Immunostimulants may result in little to no difference in respiratory‐related mortality when comparing the odds in intervention and placebo groups over a mean duration of six months (OR 0.40, 95% CI 0.15 to 1.07; 2 studies, 735 participants; low‐certainty evidence); however, the upper limit of the CI for the estimate also included the possibility of no difference between groups. Furthermore, certainty of this estimate was lessened by the inclusion of only two studies in meta‐analysis, one of which included a population of participants that may not be generalisable to a broader population of participants with COPD or chronic bronchitis (or both). </p> <p>Immunostimulants may be associated with an improvement in HRQoL scores, measured by the SGRQ, but the evidence was very uncertain. The pooled effect estimate from two studies indicated a small increase in the odds of improvement in scores with immunostimulant compared to placebo (MD −4.59, 95% CI −7.59 to −1.59), and met the MCID score of 4 units. However, the CI upper limit did not clear this threshold, and the possibility of no difference between groups could not be excluded.  </p> <p>The pooled result from five studies indicated that immunostimulants likely reduced the number of participants requiring antibiotics over a mean duration of six months (OR 0.34, 95% CI 0.18 to 0.63; 5 studies, 542 participants; moderate‐certainty evidence), with a moderate positive effect seen. This result had a low‐to‐moderate degree of heterogeneity (I<sup>2</sup> = 38%), but the direction of effect was consistent across all studies.  </p> <p>The combined data from 20 studies that reported adverse events indicated no difference in the odds of experiencing an adverse event with immunostimulant compared to placebo, over a mean duration of six months (OR 1.01, 95% CI 0.84 to 1.21; 3780 participants; high‐certainty evidence). The CI limits for the associated risk ratio did not cross the 25% risk reduction threshold for appreciable harm or benefit (RR 1.02, 95% CI 0.92 to 1.13). An additional seven studies reported no events in both study arms; hence, were not incorporated into meta‐analysis. </p> <p>We attempted to meta‐analyse data regarding the effect of immunostimulants from 17 studies that had reported on exacerbation duration; however, conclusions were unable to be drawn due to the high level of heterogeneity (I<sup>2</sup> = 92%) and probable data skew. Results from an effect direction plot and binomial probability test indicated that a significant proportion of studies reported a direction of effect that favoured intervention, possibly indicating that immunostimulants are efficacious in reducing exacerbation duration compared to placebo  (94%, 95% CI 73% to 99%; P = 0.0002). However, the degree of uncertainty associated with this estimate remained high. </p> <p>Three studies reported mean respiratory‐related hospitalisation duration, two of which demonstrated a direction of effect that favoured immunostimulant compared to placebo; effect size and direction for the other was unclear, as measures of variance were not reported and unable to be estimated. Data were not interpretable from a meta‐analysis due to high levels of heterogeneity (I<sup>2</sup> = 83%). The impact of immunostimulant on hospitalisations in general was reported using a wide variety of metrics across several studies. Three of the larger, more‐recent trials all reported reductions in total respiratory‐related hospital days over a mean duration of 10 months with immunostimulant compared to placebo.  </p> <p>For several outcomes, there was moderate‐to‐significant heterogeneity across the included studies. Therefore, results should be interpreted with caution. Outcomes where there was no heterogeneity were mortality (all‐cause), mortality (respiratory‐related), quality of life, and adverse events/side effects. Subgroup analyses were performed to investigate causes of heterogeneity for the primary outcome of number of participants with no exacerbations; however, heterogeneity remained high within subgroups. Subgroups that had low or no heterogeneity detected mostly contained small numbers of studies and participants, with non‐significant associated P values for the Chi<sup>2</sup> test for heterogeneity. </p> <p>Subgrouping did not modify the treatment effect estimate for either of the two primary outcomes; however, the validity of the estimates were limited by the degree of heterogeneity and uneven covariate distribution within some subgroups. Therefore, it was difficult to draw conclusions from these subgroup analyses.  </p> </section> </section> <section id="CD013343-sec-0076"> <h3 class="title" id="CD013343-sec-0076">Overall completeness and applicability of evidence</h3> <p>Of particular relevance to earlier trials, the definitions of chronic bronchitis or COPD (or both) in several included studies were not always well‐defined and, especially for trials involving participants with chronic bronchitis alone, were based on clinical criteria only. Only 17 studies reported lung function; of these, 13 included participants with moderate‐to‐severe airflow limitation (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). Although efforts were made to exclude those studies that may have included participants with other respiratory illnesses, such as asthma or bronchiectasis, it was not always clear what methods trialists had used to differentiate these conditions among the enrolled participants. Smoking prevalence appeared to vary widely across studies; although, many did not distinguish between the proportions of never‐smokers and ex‐smokers. Studies that were outliers with respect to mean participant age may also indicate a significant degree of disease heterogeneity across the included study participants, although the study with the lowest mean participant age was an outlier, only assessed one of the review outcomes, and was not included in meta‐analysis. All these factors may have impacted on the combinability of data within the review, contributed to the heterogeneity across several outcomes, and likely affected the generalisability of the evidence to a wider population of participants with COPD, as defined by current criteria (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). However, creating more stringent population criteria for study inclusion at the outset of this review may have excluded a significant proportion of studies, particularly older studies, which included participants based on disease definitions at the time of enrolment, as opposed to on the basis of more‐recently established and current gold‐standard diagnostic criteria. </p> <p>Most studies included participants with a history of respiratory exacerbations; however, many involved short‐to‐medium follow‐up periods (mean study duration 6.6 months). Especially in studies where exacerbation outcomes were measured over periods of less than six months, any positive treatment effect in the intervention group may have been potentially exaggerated by short time frames of outcome measurement; conversely, having shorter follow‐up periods may not have allowed exacerbations to manifest in either group, contributing to negative or non‐significant results. It is similarly difficult to extrapolate evidence around mortality to a wider population when this outcome was measured over a relatively short mean duration of 8.4 months.  </p> <p>The applicability of the results of the earlier studies is likely to be affected by a degree of publication bias; it is probable that small, negative, or neutral immunostimulant trials were unpublished based on the results of a funnel plot performed for the primary outcome (<a href="#CD013343-fig-0004">Figure 4</a>). The included smaller, positive trials were associated with much broader CIs and were given less weight in meta‐analysis; their exclusion did not appear to have a significant impact on the pooled effect estimate for the primary outcome. The effect of advances in COPD management over the years also influences interpretation of the results of the earlier, positive studies. It is unlikely that participants in these studies were exposed to what would currently be considered 'standard' non‐pharmacological and pharmacological management for COPD or chronic bronchitis (or both) (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). </p> <p>The 36 included studies reported a wide range of outcomes that were direct or surrogate markers for exacerbation frequency or severity (or both). The outcome measures chosen for this review were restricted to those that were considered to enhance combinability of the data, and we preferentially used dichotomous measures for parametric analysis as they were deemed to be more statistically robust. Some other frequently reported outcomes in the included studies included count data presented as a continuous outcome, such as 'mean number of exacerbations'; these were not included in this review due to the likelihood of skew associated with this metric. Therefore, there be a range of similar or related outcome measures reported in the included studies that were not incorporated in the review analyses but which may be of clinical relevance. </p> </section> <section id="CD013343-sec-0077"> <h3 class="title" id="CD013343-sec-0077">Quality of the evidence</h3> <p>Overall, we graded the certainty of the evidence to be moderate, meaning that the true effect is probably close to the estimate of the effect, but that further research is likely to have an important impact on our confidence in the estimate and may change the estimate (see <a href="./full#CD013343-tbl-0001">summary of findings Table 1</a>). Several considerations led to downgrades in the level of certainty in the effect estimate for most main outcomes. For individual outcomes, the level of certainty varied from very low (quality of life) to high (adverse events/side effects).  </p> <p>One outcome was downgraded for risk of bias (quality of life); the meta‐analysis only included two studies, one of which was at high risk for attrition bias and for which standard deviation data had also been imputed. Most included studies for other outcomes were at low or unclear risk of bias for each domain, and exclusion of the studies at high risk of bias by sensitivity analysis did not impact on the treatment effect estimate. Two outcomes were downgraded for inconsistency (participants with no exacerbations and participants requiring antibiotics), due to moderate levels of heterogeneity. Three outcomes were downgraded for imprecision (all‐cause mortality, respiratory‐related mortality, and quality of life), as the CIs were not sufficiently narrow to exclude the possibility of no or little effect. One outcome was downgraded for indirectness (respiratory‐related mortality); only two studies were included in this analysis, one of which examined a group of participants that were not considered to be representative of a broader population with COPD or chronic bronchitis (or both), with this characteristic being relevant to the measured outcome. One outcome was downgraded for publication bias (quality of life), as only two studies were included in the analysis produced by the same author groups; one of which was an abstract. It was considered that there was not a sufficiently large body of evidence included in the analysis to affirm the effect estimate as a true result. Although the funnel plot indicated a likely degree of likely publication bias for the outcome of participants with no exacerbations (<a href="#CD013343-fig-0004">Figure 4</a>), exclusion of the smaller, positive studies in a sensitivity analysis did not significantly alter the effect estimate, therefore this outcome was not downgraded. </p> <p>The quality of the data for the outcome of exacerbation duration was very low (not meta‐analysed or included in the summary of findings table). Results from pooled analysis were associated with a high level of heterogeneity, which was interpreted to be due to methodological and clinical diversity related to study interventions, participant characteristics and study design, potentially variable outcome definitions and measures of effect, and the use of a continuous variable. It was not always clear whether trialists reported the mean duration of individual exacerbation episodes, or whether total cumulative exacerbation days during the study period had been averaged over the number of participants. Additionally, imputation of data was required for several included studies due to measures of variance not being reported. Interpretation of data related to mean duration of respiratory‐related hospitalisations was also affected by heterogeneity between included studies in a pooled analysis and a limited number of studies reporting this outcome. </p> </section> <section id="CD013343-sec-0078"> <h3 class="title" id="CD013343-sec-0078">Potential biases in the review process</h3> <p>We attempted to minimise bias during the review process by completing a comprehensive electronic search of all published and unpublished data. When screening titles and abstracts, we used a conservative approach for inclusion, especially considering the number of studies published in non‐English languages that could not be adequately screened at the first stage without the assistance of a translator. Two review authors independently reviewed full‐text articles and extracted data using Covidence software (<a href="./references#CD013343-bbs2-0116" title="Covidence. Melbourne, Australia: Veritas Health Innovation, (accessed prior to 1 September 2022). Available at covidence.org.">Covidence</a>) to ensure standardised data extraction methods. Where studies required translation, and translators were able to confirm that the studies met initial screening criteria, we sent standardised data extraction documents to translators to complete. Where possible, we used two independent translators per study to minimise the risk of bias.  </p> <p>Not all included studies were clear regarding definitions of chronic bronchitis, COPD, or what constituted a respiratory exacerbation. We accepted the trialists' definitions of these when marking studies for inclusion, given the variability in reporting across studies. Therefore, there is the possibility that some included studies contained participants or had exacerbation criteria that were not generalisable or consistent compared to other included trials, which may have impacted on the validity and applicability of the review results.  </p> <p>Several study analyses imputed standard deviations. Where this occurred, we used conservative estimates of P values and performed calculations in accordance with accepted practices; however, assumptions may have impacted on CI overlap and potentially increased heterogeneity. In one study, it was unclear whether reported measures of variance were standard deviations or standard errors (<a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a>). We contacted the study author for clarification, but this was unable to be differentiated. Based on use of standard deviation for continuous variables elsewhere in the study, we recorded values as such. Several studies did not clearly specify the number of participants analysed at the point of relevant outcome measurements (i.e. whether the number was less than at baseline due to dropouts that had not been reported); in these cases, we used an ITT approach for assuming the number of participants at any time point of the study.  </p> <p>Several studies reported data at discrete time intervals. Where these time intervals met our criteria of outcomes being measured over at least 12 weeks, we included the interval from baseline (as opposed to later intervals) in meta‐analyses; the rationale was that we considered participants analysed during the time interval of longest follow‐up would no longer be truly 'randomised' and representative of a baseline sample of patients, and treatment effects might have been confounded by prior exposure to the medication and study dropouts during the earlier parts of the study. Treatment of the data in this way may have influenced the combinability of these studies with others that had instead analysed end‐of‐study outcomes over longer durations, which may have contributed to heterogeneity when meta‐analysing data. </p> <p>Our primary and secondary outcomes were changed following the data extraction process. This deviation from protocol was carefully considered and occurred following consensus discussion, prior to any data synthesis or analysis occurring. While the eventual outcomes were broadly congruent with our original outcomes, the ways in which these were measured were altered somewhat to suit the availability and patterns of data seen across studies; this may have introduced bias, especially if there was a degree of selective reporting of positive outcomes across studies.  </p> <p>Additionally, subgroup analyses required modification following data extraction to investigate for anticipated heterogeneity related to differences in treatment and study duration, which varied broadly across included studies. Again, these changes occurred prior to data synthesis or analysis occurring. We performed a post hoc subgroup analysis involving decade of study publication following data synthesis to further investigate heterogeneity that remained unexplained by the preplanned subgroupings. Therefore, the results of this analysis should be interpreted with caution.  </p> </section> <section id="CD013343-sec-0079"> <h3 class="title" id="CD013343-sec-0079">Agreements and disagreements with other studies or reviews</h3> <p>The 2022 GOLD guidelines have specifically mentioned use of immunostimulant or immunoregulatory agents for preventing exacerbations in adults with COPD (<a href="./references#CD013343-bbs2-0128" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. goldcopd.org/2022-gold-reports-2/ (accessed 6 March 2022).">GOLD 2022</a>). However, their widespread and routine use has been limited due to a shortage of high‐quality data regarding their efficacy, and a lack of understanding of their mechanisms of action and long‐term safety profiles. The 2022 GOLD guidelines suggest that further studies are needed to examine the effects of these agents in people who are receiving current gold‐standard COPD maintenance therapy. </p> <p>One previous systematic review found that the bacterial extracts O‐85, LW‐50020, and SL‐04 were associated with improved symptoms in people with COPD, chronic bronchitis, or both, and the meta‐analysis suggested a lessened exacerbation duration (MD −2.7, 95% CI −3.5 to −1.8). However, there was no difference between the extracts and placebo in preventing exacerbations (<a href="./references#CD013343-bbs2-0176" title="Steurer-SteyC , BachmannLM , SteurerJ , TramèrMR . Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest2004;126(5):1645-55. [10.1378/chest.126.5.1645]">Steurer‐Stey 2004</a>). Another systematic review looked at the efficacy of OM‐85 in preventing exacerbations in people with COPD or chronic bronchitis (or both). For the end point of one or more exacerbations, there was a non‐significant trend in favour of OM‐85 (RR 0.83, 95% CI 0.65 to 1.05); however, there were varied results across a range of other clinically important outcomes including hospitalisations and antibiotic use (<a href="./references#CD013343-bbs2-0175" title="SprenkleMD , NiewoehnerDE , MacDonaldR , RutksI , WiltTJ . Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD: Journal of Chronic Obstructive Pulmonary Disease2005;2(1):167-75. [PMID: 17136978]">Sprenkle 2005</a>). In 2015, one meta‐analysis and systematic review examined the effects of OM‐85 in people with COPD on exacerbation rate, in addition to several other secondary clinical end points including hospitalisation duration and antibiotic use. OM‐85 was associated with a 20% reduction in exacerbation rate (RR 0.80, 95% CI 0.65 to 0.97; P = 0.03, as reported in the text of the paper) and a 39% reduction in the incidence rate of participants using antibiotics compared with placebo (RR 0.61, 95% CI 0.48 to 0.77; reported P &lt; 0.0001) (<a href="./references#CD013343-bbs2-0158" title="PanL , JiangXG , GuoJ , TianY , LiuCT . Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of Clinical Pharmacology2015;55(10):1086-92. [DOI: 10.1002/jcph.518]">Pan 2015</a>). However, the authors concluded that there was not enough evidence to support the routine use of OM‐85 in people with COPD, suggesting that further larger‐scale trials needed to be undertaken. </p> <p>The findings of this review suggest that immunostimulants may be associated with a small increase in the odds of remaining exacerbation‐free, which is consistent with the direction of effect for exacerbation outcomes seen in <a href="./references#CD013343-bbs2-0175" title="SprenkleMD , NiewoehnerDE , MacDonaldR , RutksI , WiltTJ . Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD: Journal of Chronic Obstructive Pulmonary Disease2005;2(1):167-75. [PMID: 17136978]">Sprenkle 2005</a> and <a href="./references#CD013343-bbs2-0158" title="PanL , JiangXG , GuoJ , TianY , LiuCT . Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of Clinical Pharmacology2015;55(10):1086-92. [DOI: 10.1002/jcph.518]">Pan 2015</a>. The finding that immunostimulant was associated with a reduced proportion of participants requiring antibiotics compared to placebo is also congruent with the findings in <a href="./references#CD013343-bbs2-0158" title="PanL , JiangXG , GuoJ , TianY , LiuCT . Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of Clinical Pharmacology2015;55(10):1086-92. [DOI: 10.1002/jcph.518]">Pan 2015</a>. Although our review found a positive effect direction with respect the outcomes of exacerbation duration and respiratory‐related hospitalisation duration, data were unable to be meaningfully combined in meta‐analysis and concerns around data quality and heterogeneity impacted on our certainty of these results.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013343-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013343-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013343-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-03" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013343-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013343-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013343-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013343-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Effect direction plot and sign test for the outcome of exacerbation duration." data-id="CD013343-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-07.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Effect direction plot and sign test for the outcome of exacerbation duration.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-FIG-07.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 1: Number of participants with no exacerbations during the study period" data-id="CD013343-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 1: Number of participants with no exacerbations during the study period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 2: Participants with no exacerbations, by immunostimulant type" data-id="CD013343-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 2: Participants with no exacerbations, by immunostimulant type </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 3: Participants with no exacerbations, by baseline FEV1 " data-id="CD013343-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 3: Participants with no exacerbations, by baseline FEV1  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 4: Participants with no exacerbations, by baseline exacerbation frequency " data-id="CD013343-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 4: Participants with no exacerbations, by baseline exacerbation frequency  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 5: Participants with no exacerbations, by treatment duration" data-id="CD013343-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 5: Participants with no exacerbations, by treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 6: Participants with no exacerbations, by total study duration" data-id="CD013343-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 6: Participants with no exacerbations, by total study duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 7: Participants with no exacerbations, by decade of publication" data-id="CD013343-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 7: Participants with no exacerbations, by decade of publication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 8: Mortality (all‐cause)" data-id="CD013343-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 8: Mortality (all‐cause)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 9: Mortality (all‐cause), by immunostimulant type" data-id="CD013343-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 9: Mortality (all‐cause), by immunostimulant type </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 10: Mortality (all‐cause), by baseline FEV1" data-id="CD013343-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 10: Mortality (all‐cause), by baseline FEV1 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 11: Mortality (all‐cause), by baseline exacerbation frequency" data-id="CD013343-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 11: Mortality (all‐cause), by baseline exacerbation frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 12: Mortality (all‐cause), by treatment duration" data-id="CD013343-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 12: Mortality (all‐cause), by treatment duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 13: Mortality (all‐cause), by total study duration" data-id="CD013343-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 13: Mortality (all‐cause), by total study duration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 14: Mortality (respiratory‐related)" data-id="CD013343-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 14: Mortality (respiratory‐related)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 15: Quality of life (total score St George's Respiratory Questionnaire)" data-id="CD013343-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 15: Quality of life (total score St George's Respiratory Questionnaire) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 16: Number of participants requiring antibiotics" data-id="CD013343-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 16: Number of participants requiring antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 17: Exacerbation duration" data-id="CD013343-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 17: Exacerbation duration</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 18: Hospitalisation duration (respiratory‐related)" data-id="CD013343-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 18: Hospitalisation duration (respiratory‐related) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013343-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/urn:x-wiley:14651858:media:CD013343:CD013343-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Immunostimulant versus placebo, Outcome 19: Adverse events/side effects" data-id="CD013343-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_t/tCD013343-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Immunostimulant versus placebo, Outcome 19: Adverse events/side effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/media/CDSR/CD013343/image_n/nCD013343-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013343-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ immunostimulant vs. placebo for adults with chronic bronchitis or chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with chronic bronchitis or chronic obstructive pulmonary disease<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> immunostimulant<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with immunostimulant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of participants with no exacerbations during the study period<br/>follow‐up: mean 6.1 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.48</b><br/>(1.15 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2961<br/>(15 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,</sup><sup>c,</sup><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants likely result in a slight increase in the number of participants with no exacerbations (or inversely, result in a reduction in the number of participants with ≥ 1 exacerbations). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 100</b><br/>(6 to 9) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 100</b><br/>(71 to 80) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Mortality (all‐cause)<br/>follow‐up: mean 8.4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.64</b><br/>(0.37 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1558<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>e,</sup><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants probably result in little to no difference in all‐cause mortality.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><br/>(8 to 23) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(22 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (respiratory‐related)<br/>follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 100</b><br/>(1 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b><br/>(0.15 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>735<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunostimulants may result in little to no difference in respiratory‐related mortality.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/>assessed with: St George's Respiratory Questionnaire (SGRQ)<br/>Scale from: 0 to 100 <br/>follow‐up: mean 4.5 months<sup>h</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life was <b>37.5</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>4.59 points lower</b><br/>(7.59 lower to 1.59 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>617<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>i,</sup><sup>j,</sup><sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunostimulants may be associated with improvement in health‐related quality‐of‐life scores, but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Number of participants requiring antibiotics<br/>follow‐up: mean 6.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 0.34</b><br/>(0.18 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>542<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b,</sup><sup>l,</sup><sup>m,</sup><sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants likely result in a reduction in the number of participants requiring antibiotics. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b><br/>(21 to 48) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 100</b><br/>(33 to 63) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events/side effects<br/>follow‐up: mean 6.8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 1.01</b><br/>(0.84 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3780<br/>(20 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/>High<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Immunostimulants do not increase the number of participants with an adverse event.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 100</b><br/>(5 to 7) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 100<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b><br/>(39 to 48) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429628585692116898" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429628585692116898</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> The lowest and highest risk values are the second‐lowest and second‐highest proportions of participants with no exacerbations in the control groups from the studies included in this review. <br/><sup>b</sup> Risk of bias across most sectors for included studies was 'low' or 'unclear'. Exclusion of the studies in sensitivity analysis that were classified as 'high' risk of bias for attrition or selective reporting bias (or both) had little effect on the pooled effect estimate. No downgrade for risk of bias. <br/><sup>c</sup> Moderate clinical and statistical heterogeneity identified (I² = 53%). Heterogeneity could not be explained within subgroups. May partly be explained by variations in treatment regimens. Downgraded once.<br/><sup>d</sup> Funnel plot was asymmetrical, with several small studies demonstrating a positive effect (Figure 4). However, removal of the five smaller, positive studies by sensitivity analysis demonstrated no impact on the pooled estimate. Not downgraded. <br/><sup>e</sup> Study contributing the most weight in the analysis involved an elderly population with significant comorbidity, which may limit applicability of results to a general COPD/chronic bronchitis population. However, no impact on the pooled effect estimate when excluded in sensitivity analysis. No downgrade. <br/><sup>f</sup> Small number of events. Confidence intervals included the null effect and limited suggest that intervention may decrease or increase mortality. Downgraded once for imprecision.<br/><sup>g</sup> Study contributing the most weight in analysis involved an elderly population with significant comorbidity, which may limit applicability of results to a general COPD/chronic bronchitis population. Given there are only two studies in this meta‐analysis, downgraded once for indirectness.<br/><sup>h</sup> Lower score indicates better quality of life. <br/><sup>i</sup> One of two studies presented as abstract only and judged to be 'high' risk for attrition bias. Downgraded once for risk of bias. <br/><sup>j</sup> The minimally clinically important difference (MCID) for SGRQ is 4 points. The confidence interval did not include the null effect but the lower limit did not clear the MCID. Downgraded once for imprecision. <br/><sup>k</sup> Two studies included in meta‐analysis, from the same author groups. One study was presented as an abstract. Uncertain that there was a large enough body of evidence to affirm this as a true result. Downgraded once for risk of publication bias. <br/><sup>l</sup> Moderate clinical heterogeneity (I² = 38%) likely due to clinical and methodological diversity; however, uniform direction of effect estimate across individual studies. Downgraded once.<br/><sup>m</sup> One included study involved participants with COPD and 'borderline immune deficiency'. Exclusion of this study by sensitivity analysis did not have an effect on the pooled effect estimate. Not downgraded. <br/><sup>n</sup> Confidence interval limit for risk ratio crossed the 25% relative risk reduction threshold; however, did not include the null effect and optimal information size (OIS) criteria were met. Not downgraded. <br/><sup>o</sup> The confidence interval included the null effect, but the limits did not cross the 25% relative risk threshold for appreciable benefit or harm and OIS criteria were met. Not downgraded. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ immunostimulant vs. placebo for adults with chronic bronchitis or chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013343-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study duration (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participant type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Presence of acute exacerbation as an inclusion criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (total duration)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Route</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relevant outcomes measured</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0001" title="Alvarez-MonM , MiravitllesM , MoreraJ , CallolL , Alvarez-SalaJL . Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest2005;127(4):1212-8. [DOI: 10.1378/chest.127.4.1212]MiravitllesM , MurioC , MoreraJ , CallolL , Alvarez-SalaJL , Alvarez-MonM . Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups. Medicina Clinica2008;130(18):688-92. ">Alvarez‐Mon 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3 </p> <p>1 g 3 times daily (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, SGRQ score, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0002" title="Alvarez-SalaJL , Alvarez-MonM . Treatment with Cellmune(TM) (AM3), an oral immunomodulator, increases the quality of life of chronic obstructive pulmonary disease (COPD) patients. Respiratory Care2003;48(11):1071. ">Alvarez‐Sala 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3 </p> <p>3 g daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SGRQ score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0003" title="AnthoineD , BlaiveB , CabanieuG , ChretienJ , DanrigalA , DucreuzetC , et al. Double-blind study of Biostim in the prevention of superinfection in patients with chronic bronchopathy. Revue de Pneumologie Clinique1985;41(3):213-7. ">Anthoine 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> <p>(data extracted limited to COPD patient subset)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740 (Biostim)</p> <p>2 mg daily for 8 consecutive days in first month; 1 mg daily for 8 consecutive days in second/third months (3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, exacerbation duration, number of participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0004" title="BisettiA , CiappiG , BariffiF , CatenaE , RoccoV , VaccaroL , et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis. Arzneimittel-Forschung1994;44(12A):1499-502. ">Bisetti 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pidotimod </p> <p>800 mg daily (2 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0005" title="BlaiveB , DemichelisB , LemoigneF , ClaryC , MaconeF . Effectiveness of vaccination by ribosomal extracts in the preventive treatment of infections episodes in chronic bronchopathies. Medecine et Maladies Infectieuses1982;12(8):475-9. ">Blaive 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> <p>(asthma patient subset excluded from analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D53 (Ribomunyl)</p> <p>4 sequences of 15 days of aerosol treatment separated by 1‐week intervals. Subcutaneous injections days 7 and 14 of first sequence and day 14 of following sequences (2.7 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aerosol and subcutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, participants with no or a reduction in antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0006" title="BondeJ , DahlR , EdelsteinR , Kok-JensenA , LazerL , PunakiviL , et al. The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. European Journal of Respiratory Diseases1986;69(4):235-41. ">Bonde 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740 (Biostim)</p> <p>2 mg daily or 8 mg daily (2 intervention groups) for 1 week, alternate weeks (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, exacerbation duration, duration of antibiotic therapy, AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0007" title="BongiornoA , CataldoMG , MazzolaG , IndovinaI . Controlled versus placebo study of the efficacy and tolerance of a new immunomodulator AM3 (immunoferon) in chronic bronchitis. Ciencia Medica1989;6(9):357-62. ">Bongiorno 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3 </p> <p>500 mg 3 times daily (4 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, number of exacerbations, exacerbation duration, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0008" title="BraidoF , MelioliG , CazzolaM , FabbriL , BlasiF , MorettaL , et al. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: a multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology &amp; Therapeutics2015;33:75-80. [DOI: 10.1016/j.pupt.2015.03.006]EUCTR2007-000006-67-IT. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate or severe and very severe chronic obstructive pulmonary disease (COPD) according to GOLD classification: a multicenter, international, double blind, randomized, controlled, phase IV study. hwww.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000006-67-IT (first received 8 June 2009). ">Braido 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ismigen</p> <p>50 mg daily for 10 consecutive days/month for 3 months, then 3 months without treatment, then repeat of the initial regimen (9 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyvalent mechanical bacterial lysate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, exacerbation rate, days to first exacerbation, hospitalisation days (respiratory and all‐cause), participants requiring concomitant medications, QoL scale scores, AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0009" title="Carlo M Sr, Carlo M Jr. Double blind study controlled with placebo of a new immunomodulator substance. Geriatrika1990;6(6):65-9. ">Carlo 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3</p> <p>500 mg 3 times daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Candida utilis</i> polysaccharide/protein compound  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0010" title="CatenaE , GrassiC , GrossiE . Efficacy of treatment with thymomodulin in the profilaxis of exacerbations in COPD patients with cell-mediated deficit. Giornale Italiano della Malattie del Torace1992;46(3):193-202. ">Catena 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD plus "cell‐mediated immune deficiency"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymomodulin </p> <p>60 mg twice daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, QoL scale scores, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0011" title="CazzolaM . A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial. Luglio2006;6(3):191-9. ">Cazzola 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ismigen</p> <p>50 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyvalent mechanical bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, exacerbation duration, duration of antibiotic therapy, hospitalisation rate (respiratory), hospitalisation duration (respiratory), hospitalisation days (respiratory), AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0012" title="CiacciaA , ZavattiniG , FerriP . Pidotimod in the treatment of chronic bronchitis exacerbations. Giornale Italiano delle Malattie del Torace1993;47(1-2):27-33. CiacciaA . Pidotimod activity against chronic bronchitis exacerbations. Arzneimittel-Forschung1994;44(12A):1516-20. ">Ciaccia 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pidotimod</p> <p>800 mg daily (2 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, days to first exacerbation, exacerbation duration, duration of antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0013" title="ColletJP , ShapiroP , ErnstP , RenziT , DucruetT , RobinsonA . Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. American Journal of Respiratory and Critical Care Medicine1997;156(6):1719-24. [DOI: 10.1164/ajrccm.156.6.9612096]">Collet 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85 </p> <p>7 mg daily for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (4 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, hospitalisation rate (respiratory and all‐cause), participants requiring hospitalisation (respiratory and all‐cause), hospitalisation duration (respiratory), hospitalisation days (respiratory and all‐cause), mean number of hospital days per participant (respiratory), change in SF‐36 scale scores, AEs, mortality (respiratory and all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0014" title="CvoriscecB , UstarM , PardonR , PalecekI , Stipic-MarkovicA , ZimicB . Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration; International Review of Thoracic Diseases1989;55(3):129-35. [DOI: 10.1159/000195723]">Cvoriscec 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation duration, total exacerbation days, participants requiring antibiotics, participants requiring bronchodilator therapy, FEV1, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0015" title="DebbasN , DerenneJP . Preventive effects of immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung1990;168:737-40. ">Debbas 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, participants requiring antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0016" title="De BernardiM , PedrinazziPM , ReA , ColomboP , FabianiA , ZanasiA . Immunostimulation induced by bacterial lysates in chronic bronchitis. A double blind placebo controlled clinical study. Acta Toxicologica et Therapeutica1992;13(2):73-92. ">De Bernardi 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB plus "borderline immune deficiency"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lantigen B (2 intervention groups)</p> <p>15 drops twice daily for 1 month, then 1 month without treatment, then a 15 days of initial regimen (2.5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sublingual </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0017" title="DjuricO , Mihailovic-VucinicV , StojcicV . Effect of Broncho-Vaxom on clinical and immunological parameters in patients with chronic obstructive bronchitis. A double-blind, placebo-controlled study. International Journal of Immunotherapy1989;5(3):139-43. ">Djuric 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, duration of concomitant therapy, FEV1 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0018" title="EUCTR2007-004702-27-DE. Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® (Broncho-Munal®) for the protection from acute exacerbations of COPD. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-004702-27-DE (first received 7 December 2007). ">EUCTR2007‐004702‐27‐DE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, exacerbation duration, days to first exacerbation, duration of concomitant therapy, hospitalisation rate and duration (all‐cause), SGRQ scores, FEV1, AEs/serious AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0019" title="FiettaA , BersaniC , De RoseV , MangiarottiP , MerliniC , UccelliM , et al. Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration; International Review of Thoracic Diseases1988;54(3):145-52. [DOI: 10.1159/000195515]">Fietta 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740 (Biostim)</p> <p>2 mg daily for 8 consecutive days in first month; 1 mg daily for 8 consecutive days in second/third months (3 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, exacerbation duration, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0020" title="FoschinoBM , RestaO , CassanoA , AltieriA , GuidoP , PitiA , et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants. Minerva Pneumologica1995;34(2):39-44. ">Foschino 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D53 (Ribomunyl)</p> <p>1 tablet (dose not specified) daily for 4 consecutive days/week for 3 weeks, then 1 tablet daily for 4 consecutive days/month for 5 months (5.75 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0021" title="HabermannW , ZimmermannK , SkarabisH , KunzeR , RuschV . The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic recurrent bronchitis. Arzneimittel-Forschung2001;51(11):931-7. ">Habermann 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symbioflor</p> <p>30 drops 3 times daily (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral vs sublingual (liquid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, days to first exacerbation, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0022" title="HutasI , KraszkoP , Boszormenyi NagyG . Immunomodulation therapy in chronic bronchitis (multicenter study). Orvosi Hetilap1994;135(23):1251-4. ">Hutas 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation duration, duration of antibiotic therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0023" title="KellerR , HinzG . Effect of an oral polyvalent bacterial lysate (Broncho-Vaxom) in chronic bronchitis. Praxis und Klinik der Pneumologie EMT1984;38(6):225-8. KellerR . Multicenter double-blind study of the action of Broncho-Vaxom in chronic bronchitis. Schweizerische Medizinische Wochenschrift1984;114(25):934-7. ">Keller 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations, duration of antibiotic therapy, duration of corticosteroid therapy, hospitalisation rate (respiratory) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0024" title="LiJ , ZhengJP , YuanJP , YangL , LuoDF , AnJY , et al. Protection of oral immunostimulant bronchovaxom against with chronic obstructive pulmonary disease. Respirology2005;10(3):A137. LiJ , ZhengJP , YuanJP , ZengGQ , ZhongNS , LinCY . Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chinese Medical Journal2004;117(6):828-34. ">Li 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, duration of antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0025" title="MenardoJL , DussolJP , BetbederA . Immunotherapy of respiratory infection by oral immunomodulation in chronic obstructive bronchopneumopathy. Medecine et Hygiene1985;43(1623):2722-6. ">Menardo 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diribiotine CK</p> <p>10 mL daily for 20 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral (liquid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, exacerbation duration, participants requiring antibiotics, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0026" title="MesserliC , MichettiF , Sauser-HallP , StäubliC , TaddeiM , WeissS , et al. Effect of a bacterial lysate (Broncho-Vaxom) in the therapy of chronic bronchitis: multi-center double-blind clinical trial. Revue Médicale de la Suisse Romande1981;101(2):143-6. ">Messerli 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0027" title="OlivieriD . Reducing exacerbations in COPD with OM-85: a multicentre, double-blind, placebo-controlled trial. European Respiratory Journal2011;38(55):9s. ">Olivieri 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation rate, exacerbation duration, AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0028" title="OrcelB , DelclauxB , BaudM , DerenneJP . Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal1994;7(3):446-52. OrcelB , DelclauxB , BaudM , DerenneJP . Preventive effect of an immunomodulator, OM-85 BV, on acute exacerbations of chronic bronchitis in elderly patients. Preliminary results at six months in 291 patients. Revue des Maladies Respiratoires1993;10(1):23-8. ">Orcel 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, mean number of antibiotic courses, participants requiring bronchodilator therapy, participants requiring corticosteroids, AEs, mortality (respiratory and all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0029" title="OrlandiO , BrunaS , BagnascoG . Immunostimulation treatment with a bacteriolysate in recurring bacterial infections in chronic bronchitics. Minerva Pneumologica1983;22:461-4. ">Orlandi 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (4 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, hospitalisation duration (respiratory), mean number of hospitalisations per participant (respiratory), AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0030" title="Rico MendezFG , Tellez DiazE , Garcia SanchoC , Sanchez DiazR , Yoma MedinaJ . Efficacy and prevention with thymomodulin on the numbers and duration of respiratory infectious episodes in adults with chronic obstructive lung disease. Revista Alergia Mexico1997;44(4):93-101. ">Rico 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymomodulin</p> <p>80 mg 3 times daily (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, hospitalisation duration (all‐cause), mean number of concomitant medication courses, duration of concomitant therapies, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0031" title="RochemaureJ , LehertP , SauvagetJ , RobillardM , Betbeder-MatibetA . Reduction using an immunomodulator of the level of respiratory infections in chronic bronchitis. Revue de Pneumologie Clinique1988;44(1):43-7. RochemaureJ , LehertP , SauvagetJ , RobillardM , MurrayN , CastanierJC . Usefulness of immunomodulating agents. Lancet1987;2(8559):101. ">Rochemaure 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diribiotine CK</p> <p>10 mL daily for 20 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral (liquid preparation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, mean number of antibiotic courses, duration of antibiotic therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0032" title="SolerM , MutterleinR , CozmaG , on behalf of the Swiss-German OM Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration2007;74(1):26-32. [DOI: 10.1159/000093933]SolerM , MutterleinR , CozmaG . Prevention of exacerbations in chronic bronchitis and COPD with OM-85, a double-blind, placebo-controlled trial. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL). D22[Poster 506]. ">Soler 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, mean number of exacerbations per participant, number of exacerbations, participants requiring concomitant medication, AEs, mortality (all‐cause) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0033" title="TagE , AshmawiS , EmamWE . Effect of a polyvalent bacterial extract, Broncho-Vaxom, in the prophylaxis of acute exacerbations of chronic bronchitis. European Journal of Clinical Research1993;4:99-105. ">Tag 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number of exacerbations per participant, exacerbation duration, duration of antibiotic therapy, duration of bronchodilator therapy, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0034" title="TangH , FangZ , SaborioGP , XiuQ . Efficacy and safety of OM-85 in patients with chronic bronchitis and/or chronic obstructive pulmonary disease. Lung2015;193(4):513-9. [DOI: 10.1007/s00408-015-9737-3]TangH , FangZ , XiuQ . Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. European Respiratory Journal2011;38(55):599s. ">Tang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 10 consecutive days/month for 3 months (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, participants requiring concomitant medication, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0035" title="VengeP , PedersenB , HakanssonL , HallgrenR , LindbladG , DahlR . Subcutaneous administration of hyaluronan reduces the number of infectious exacerbations in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine1996;153(1):312-6. [DOI: 10.1164/ajrccm.153.1.8542136]">Venge 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CB/COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyaluronan</p> <p>7.5 mg subcutaneously weekly (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with/without an exacerbation, number of exacerbations, total exacerbation days, total antibiotic days, AEs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013343-bbs2-0036" title="XinogalosS , DuratsosD , VaronosD . Clinical effectiveness of Broncho-Vaxom (BV) in patients with chronic obstructive pulmonary disease. International Journal of Immunotherapy1993;9(2):135-42. ">Xinogalos 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> <p>7 mg daily for 1 month, no treatment for 1 month, then 7 mg daily for 10 consecutive days/month for 3 months (5 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations, exacerbation duration, participants requiring antibiotics, participants requiring bronchodilator therapy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AE: adverse events; CB: chronic bronchitis; COPD: chronic obstructive pulmonary disease; QoL: quality of life; SF‐36: 36‐item Short Form Survey; SGRQ: St George's Respiratory Questionnaire.<br/><sup>a</sup>Total n: number of participants for whom outcome data were available. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013343-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Immunostimulants included in this review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trade name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Generic name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Active entity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pidotimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RU41740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived (glycoproteins and membrane fractions of <i>Klebsiella pneumoniae</i>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Broncho‐Vaxom, Broncho‐Munal, Ommunal, Paxoral, Vaxoral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OM‐85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diribiotine CK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hymovis, Monovisc, Orthovisc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyaluronan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Synthetic agent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Immunoferon, Inmunol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AM3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycophosphopeptical (polysaccharide and protein compounds of <i>Candida utilis</i>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ismigen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polyvalent mechanical bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lantigen B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial lysate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ribomunyl, Ribovac, Immucytal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived (proteoglycans of <i>Klebsiella pneumoniae</i> and ribosomal fragments from a range of bacterial pathogens) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymolin, Leucotrofina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymomodulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thymic extract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symbioflor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteria‐derived (components of <i>Enterococcus faecalis</i>) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Immunostimulants included in this review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/full#CD013343-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013343-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Immunostimulant versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of participants with no exacerbations during the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Participants with no exacerbations, by immunostimulant type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 OM‐85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.97, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 AM3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.83, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Biostim</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.00, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.88, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Participants with no exacerbations, by baseline FEV1  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.06, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 FEV1 ≥ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.03, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.87, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Participants with no exacerbations, by baseline exacerbation frequency  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Mean exacerbation rate ≥ 2 in preceding year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.13, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Mean exacerbation rate &lt; 2 in preceding year or not specified </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.87, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Participants with no exacerbations, by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Duration ≤ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.23, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.93, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Participants with no exacerbations, by total study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Duration 3 to &lt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.72, 7.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Duration 6 to &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.14, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Duration ≥ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Participants with no exacerbations, by decade of publication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Years 2010–2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.79, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Years 2000–2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.87, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Years 1990–1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.96, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Years 1980–1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.27, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Mortality (all‐cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Mortality (all‐cause), by immunostimulant type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 OM‐85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Ismigen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.14, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Mortality (all‐cause), by baseline FEV1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.38, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 FEV1 ≥ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.42, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.11, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Mortality (all‐cause), by baseline exacerbation frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Mean exacerbation rate ≥ 2 in preceding year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.38, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Mean exacerbation rate &lt; 2 in preceding year or not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.13, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Mortality (all‐cause), by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Duration ≤ 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.39, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Duration &gt; 3 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.14, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Mortality (all‐cause), by total study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.37, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Duration 6 to &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Duration ≥ 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.14, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Mortality (respiratory‐related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.15, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Quality of life (total score St George's Respiratory Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.59 [‐7.59, ‐1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Number of participants requiring antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.18, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Exacerbation duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Hospitalisation duration (respiratory‐related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Adverse events/side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Immunostimulant versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013343.pub2/references#CD013343-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013343.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013343-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013343-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013343-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD013343-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013343-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013343-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013343-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013343\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013343\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013343\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013343\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013343\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013343.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013343.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013343.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013343.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013343.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717255715"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013343.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717255719"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013343.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db3761ccc9365',t:'MTc0MDcxNzI1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 